




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07D 263/14, 413/04, A61K 31/421, 31/422, C07D 471/04, 263/10 // (C07D 471/04, 235:00, 221:00) (C07D 471/04, 221:00, 209:00)	A1	(11) International Publication Number: WO 00/06556 (43) International Publication Date: 10 February 2000 (10.02.00)
(21) International Application Number: PCT/US99/16782 (22) International Filing Date: 23 July 1999 (23.07.99) (30) Priority Data: 09/122,973 27 July 1998 (27.07.98) US (71) Applicant: ABBOTT LABORATORIES [US/US]; CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-6050 (US). (72) Inventors: GWALTNEY, Stephen, L., II; 259 Quail Court, Lindenhurst, IL 60046 (US). JAE, Hwan-Soo; 477 Wood- lawn Avenue, Glencoe, IL 60022 (US). KALVIN, Douglas, M.; 1201 Lockwood Drive, Buffalo Grove, IL 60089 (US). LIU, Gang; 838 Adderly Lane, Gurnee, IL 60031 (US). SHAM, Hing, L.; 212 Knightsbridge Drive, Mundelein, IL 60060 (US). LI, Qun; 1417 Castleton Road, Libertyville, IL 60048 (US). CLAIBORNE, Akiyo, K.; 73 S. Windsor Place, Mundelein, IL 60060 (US). WANG, Le; 20 South Parliament Way, Mundelein, IL 60060-3224 (US). BARR, Kenneth, J.; 1711 Funston, San Francisco, CA 94122 (US). WOODS, Keith, W.; Apartment 303, 200 Red Top Drive, Libertyville, IL 60048 (US).		(74) Agents: STEELE, Gregory, W. et al.; Abbott Laboratories, CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: SUBSTITUTED OXAZOLINES AS ANTIPROLIFERATIVE AGENTS <div style="text-align: center;"> (I)</div> (57) Abstract <p>Compounds having Formula (I) are useful for treating cancer. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I), and methods of treating cancer in a mammal.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

SUBSTITUTED OXAZOLINES AS ANTIPROLIFERATIVE AGENTS

Technical Field

5 The present invention relates to substituted oxadiazolines which are useful for treating pathological states which arise from or are exacerbated by cell proliferation, to pharmaceutical compositions comprising these compounds, and to methods of inhibiting cell proliferation in a mammal.

10 Background of The Invention


 Neoplastic diseases are characterized by the proliferation of cells which are not subject to normal cell growth and are a major cause of death in humans and other mammals. Cancer chemotherapy has not only provided new and more effective drugs to treat these diseases but has also demonstrated that drugs which disrupt the microtubule
15 system of the cytoskeleton are effective in inhibiting the proliferation of neoplastic cells.

 The microtubule system of eucaryotic cells is a major component of the cytoskeleton and is a dynamic assembly and disassembly wherein heterodimers of tubulin are polymerized and form microtubule. Microtubules play a key role in the regulation of cell architecture, metabolism, and division and in their dynamic state are critical to normal
20 cell function. With respect to cell division, tubulin is polymerized into microtubules that form the mitotic spindle. The microtubules are then depolymerized when the mitotic spindle's use has been fulfilled. Accordingly, agents which disrupt the polymerization or depolymerization of microtubules, and thereby inhibit mitosis, comprise some of the most effective cancer chemotherapeutic agents in clinical use. Thus agents which have the
25 ability to disrupt the microtubule system are useful for cancer treatment.

 Certain cryptophycin compounds are disclosed in U.S. Patent Nos. 4,946,835, 4,845,085, 4,845,086, and 4,868,208; however, compounds having greater metabolic stability and longer duration of action are desired for most therapeutic uses. Thus there is still a need for compounds which inhibit mitosis.

Summary of The Invention

In one embodiment of the invention is disclosed compounds having Formula I



or a pharmaceutically acceptable salt or prodrug thereof, wherein

5 R^A , R^B , and R^C are independently selected from the group consisting of

- (1) alkyl,
- (2) alkoxy,
- and
- (3) thioalkoxy;

10

R^D and R^E are independently selected from the group consisting of

- (1) hydrogen
- and
- (2) alkyl;

15

R^2 is selected from the group consisting of

- (1) aryl,
- (2) heterocycle,

wherein (1) and (2) can be optionally substituted with one, two, three, four, or five

20

substituents independently selected from $-L^1R^6$ wherein L^1 is selected from the group consisting of

- (a) a covalent bond,
- (b) $-C(X)-$, wherein X is O or S,
- (c) $-S(O)_t-$, wherein t is 0, 1, or 2,

25

(d) $-NR^3-$, wherein R^3 is selected from the group consisting of

- (i) hydrogen,
- (ii) carboxaldehyde,
- (iii) alkanoyl,
- (iv) alkoxycarbonyl,

30

- (v) $-C(O)OR^{11}$, wherein R^{11} is alkyl which can be optionally substituted with one or two aryl substituents,
- (vi) cycloalkyl,

- (vii) alkyl, wherein the alkyl can be optionally substituted with one or two substituents independently selected from the group consisting of
 (1') alkoxy,
 (2') cycloalkyl,
 5 and
 (3') aryl, wherein the aryl can be optionally substituted with one or two substituents independently selected from the group consisting of
 (a') alkanoyloxy,
 10 (b') hydroxy,
 and
 (c') alkoxy,
 (viii) alkenyl,
 (ix) alkynyl,
 15 (x) $-OR^5$ wherein R^5 is selected from the group consisting of
 (1') hydrogen,
 and
 (2') alkyl, wherein the alkyl can be optionally substituted with one or two substituents independently selected from the group consisting of
 20 (a') aryl,
 (b') cycloalkyl,
 and
 (c') hydroxyl,
 25 (xi) a nitrogen protecting group,
 (xii) aryl,
 and
 (xiii) $-C(O)R^{13}$, wherein R^{13} is perfluoroalkyl,
 (e) $-O-$,
 30 (f) $-X'C(X)-$, wherein X is defined previously and X' is O or S,
 (g) $-C(X)X-$,
 (h) $-N(R^{3'})C(O)N(R^{4'})-$ wherein $R^{3'}$ and $R^{4'}$ are independently selected from the group consisting of
 (i) hydrogen
 35 and
 (ii) alkyl,

(i) $-N(R^{3'})C(X)-$, wherein $R^{3'}$ is defined above,

(j) $-C(X)N(R^{3'})-$, wherein $R^{3'}$ is defined above,

(k) $-NR^{3'}S(O)_t-$, wherein $R^{3'}$ is defined above,

and

5 (l) $-S(O)_tNR^{3'}$ - wherein t and $R^{3'}$ are defined above,

wherein (a)-(l) are drawn with their left ends attached to $-L^1-$ and their right ends attached to R^6 , and R^6 is selected from the group consisting of

(a) $-CO_2R^5$, wherein R^5 is defined above,

(b) $-C(O)R^5$, wherein R^5 is defined above,

10 (c) $-OC(O)R^{10}$, wherein R^{10} is alkyl which can be optionally substituted with one or two substituents selected from the group consisting of

(i) alkoxy

and

(ii) hydroxy,

15 (d) cyano,

(e) nitro,

(f) $-XH$,

(g) halo,

(h) $-S(O)_tNR^3R^4$, wherein R^3 is defined above, t' is one or two, and R^4 is selected

20 from the group consisting of

(i) hydrogen,

(ii) carboxaldehyde,

(iii) alkanoyl,

(iv) $-C(O)OR^{10}$, wherein R^{10} is defined above,

25 (v) $-C(O)OR^{11}$, wherein R^{11} is defined above,

(vi) cycloalkyl,

(vii) alkyl, wherein the alkyl can be optionally substituted with one or two substituents independently selected from the group consisting of

(1') $-OR^{10}$, wherein R^{10} is defined above,

30 (2') cycloalkyl,

and

(3') aryl, wherein the aryl can be optionally substituted with one or two substituents independently selected from the group consisting of

35 (a') $-OC(O)R^{10}$, wherein R^{10} is defined above,

(b') hydroxyl,

and

(c') -OR¹⁰, wherein R¹⁰ is defined above,

(viii) alkenyl,

(ix) alkynyl,

and

(x) -OR⁵, wherein R⁵ is defined above,

(i) -NR³R⁴, wherein R³ and R⁴ are defined above,

(j) perfluoroalkyl,

(k) alkenyl,

(l) alkynyl,

(m) aryl,

(n) heterocycle,

(o) alkyl,

(p) cycloalkyl,

and

(q) =X, wherein X is defined above,

wherein (k)-(o) can be optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of

(i) hydroxyl,

(ii) halo,

(iii) -OR¹⁰, wherein R¹⁰ is defined above,

(iv) -SR¹⁰, wherein R¹⁰ is defined above,

(v) -CO₂R⁵, wherein R⁵ is defined above,

(vi) carboxaldehyde,

(vii) =X, wherein X is defined above,

(viii) azido,

(ix) =C(H)NR³R⁴, wherein R³ and R⁴ are defined above,

(x) cyano,

(xi) =NOR³, wherein R³ is defined above,

(xii) -NR³R⁴, wherein R³ and R⁴ are defined above,

(xiii) -S(O)_tNR³R⁴, wherein R³ and R⁴ are defined above,

(xiv) nitro,

(xv) aryl,

and

(xvi) heterocycle,

(4) cycloalkyl,

and

(5) cycloalkenyl,

wherein (4) and (5) can be optionally substituted with one, two, three, or four substituents independently selected from the group consisting of

- 5 (a) alkyl,
(b) hydroxyl,
and
(c) aryl.

10 In another embodiment of the invention are disclosed methods of treating cancer comprising administering an effective amount of a compound having Formula I.

In yet another embodiment of the invention are disclosed pharmaceutical compositions containing compounds of Formula I.

Compounds of the invention include, but are not limited to,

- 15 2-(4-dimethylaminophenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(3-hydroxy-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(3,5-dimethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(3-acetylmethylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(1-methylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
20 2-(indol-3-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(indol-2-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(1-methoxymethylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(4-amino-3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(indol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
25 2-(4-amino-3-methylphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(3-hydroxy-4-methoxyphenyl)-4-dimethyl-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(N-methyl-tetrahydroquinol-6-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(2-methyl-cyclopropyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
30 2-(4-ethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(3,4-dimethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(4-benzyloxy-3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(2,3-dihydro-5-bromo-7-benzofuranyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
35 2-(3-acetoxy-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(1-methyl-2,3-dihydro-indol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(1-methylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline, hydrochloride,

- (5S)-2-(1-methylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 (5R)-2-(1-methylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(1-ethylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(6-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 5 2-(1-methylindol-6-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(4-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(1-methylindol-4-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(7-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(1-methylindol-7-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 10 2-(1-methylindol-3-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(1-methyl-indol-2-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(6-quinolinyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(3-quinolinyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(4-quinolinyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 15 2-(1-isoquinolinyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(3-amino-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(3-amino-4-methylphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(3-(Ala-Ala-amino-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 20 2-(3-(Ala-amino-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(3-((3-aminopropionoyl)amino-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(3-(Ser-amino-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(3-(Gly-amino-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 25 2-(1-methyl-1*H*-pyridin-2-on-4-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(2-(2-hydroxyethyloxy)-4-pyridinyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(imidazo[1,2-*a*]pyridin-6-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(imidazo[1,5-*a*]pyridin-6-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 30 2-(2-methyl-6-indoliziny)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(3-fluoro-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-((2*S*)-indolin-2-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(2-chloro-4-nitrophenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(2-fluoro-4-nitrophenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline.
 35 2-(1,4-dimethylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 (2-(1-methylthiothiocarbonylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,

2-(1,3-dimethylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(6-chloroindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(1-methyloxindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(1-methyl-6-chloroindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 5 2-(1-difluoromethylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(3-chloro-1-methylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(7-fluoro-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(1-methyl-7-fluoro-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(7-chloro-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 10 2-(1-methyl-7-chloro-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(3-fluoro-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 (2-(1-methyl-3-fluoro-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(1-hydroxymethylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(1-methoxymethyl-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 15 2-(1,2-dimethyl-5-indolyl)-4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(7-methyl-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(1,7-dimethyl-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(1,2,7-trimethylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(1,2-dimethylbenzimidazol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 20 2-(3-trifluoroacetyl-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 (2-(1-methyl-3-trifluoroacetylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 oxazoline,

2-(1-(2,2,2-trifluoroethyl)indol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,

and

25 2-(1-cyclopropyl-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline.

Detailed Description of the Invention

Definition of Terms

The term "alkanoyl," as used herein, refers to an alkyl group attached to the parent molecular group through a carbonyl group.

30 The term "alkanoyloxy," as used herein, refers to an alkanoyl group attached to the parent molecular group through an oxygen atom. The alkanoyloxy groups of this invention can be optionally substituted.

The term "alkenyl," as used herein, refers to a monovalent straight or branched chain group of 2-6 carbon atoms containing at least one carbon-carbon double bond.

35 The term "alkoxy," as used herein, refers to an alkyl group attached to the parent molecular group through an oxygen atom.

The term "alkoxycarbonyl," as used herein, refers to an alkoxy group attached to the parent molecular group through a carbonyl group.

The term "alkyl," as used herein, refers to a saturated straight or branched chain group of 1-6 carbon atoms derived from an alkane by the removal of one hydrogen atom.

5 The alkyl groups of this invention can be optionally substituted.

The term "alkynyl," as used herein, refers to a monovalent straight or branched chain group of 2-6 carbons containing at least one carbon-carbon triple bond. The alkynyl groups of this invention can be optionally substituted.

10 The term "aryl," as used herein, refers to a mono- or bicyclic carbocyclic ring system having 1 or 2 aromatic rings. The aryl group can also be fused to a cyclohexane, cyclohexene, cyclopentane or cyclopentene ring. The aryl groups of this invention can be optionally substituted.

The term "azido," as used herein, refers to $-N_3$.

The term "carboxaldehyde," as used herein, refers to $-CHO$.

15 The term "carbonyl," as used herein, refers to $-C(O)-$.

The term "cyano," as used herein, refers to $-CN$.

The term "carboxaldehyde," as used herein, refers to $-CHO$.

20 The term "cycloalkenyl," as used herein, refers to a monovalent group derived from a cyclic or bicyclic hydrocarbon of 3-12 carbons that has at least one carbon-carbon double bond.


The term "cycloalkyl," as used herein, refers to a monovalent group 3-12 carbons derived from a saturated cyclic or bicyclic hydrocarbon.

The term "halo," as used herein, refers to $-F$, $-Cl$, $-Br$, or $-I$.

25 The term "heterocycle," as used herein, represents a represents a 4-, 5-, 6- or 7-membered ring containing one, two or three heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur. The 4- and 5-membered rings have zero to two double bonds and the 6- and 7-membered rings have zero to three double bonds. The term "heterocycle" also includes bicyclic, tricyclic and tetracyclic groups in which any of the above heterocyclic rings is fused to one or two rings independently selected from an aryl ring, a cyclohexane ring, a cyclohexene ring, a cyclopentane ring, a cyclopentene ring or another monocyclic heterocyclic ring. Heterocycles include acridinyl, benzimidazolyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, biotinyl, cinnolinyl, dihydrofuryl, dihydroindolyl, dihydropyranyl, dihydrothienyl, dithiazolyl, furyl, homopiperidinyl, imidazolidinyl, imidazolinyl, imidazolyl, indolyl, 30 isoquinolyl, isothiazolidinyl, isothiazolyl, isoxazolidinyl, isoxazolyl, morpholinyl, oxadiazolyl, oxazolidinyl, oxazolyl, piperazinyl, piperidinyl, pyranyl, pyrazolidinyl, pyrazinyl, pyrazolyl, pyrazolinyl, pyridazinyl, pyridyl, pyrimidinyl, pyrimidyl,

pyrrolidinyl, pyrrolinyl, pyrrolyl, quinolinyl, quinoxaloyl, tetrahydrofuryl, tetrahydroisoquinolyl, tetrahydroquinolyl, tetrazolyl, thiadiazolyl, thiazolidinyl, thiazolyl, thienyl, thiomorpholinyl, triazolyl, imidazo[1,2-*a*]pyridinyl, 1,2-dihydropyridinyl, imidazo[1,5-*a*]pyridine, indolizine, 2,3,3a,7a-tetrahydro-1*H*-indole, and the like.

5 Heterocyclics also include bridged bicyclic groups where a monocyclic heterocyclic group is bridged by an alkylene group such as



Heterocyclics also include compounds of the formula

10 where X* is selected from -CH₂-, -CH₂O- and -O-, and Y* is selected from -C(O)- and -(C(R'')₂)_v -, where R'' is hydrogen or alkyl of one to four carbons, and v is 1-3. These heterocycles include 1,3-benzodioxolyl, 1,4-benzodioxanyl, and the like. The heterocycle groups of this invention can be optionally substituted.

The term "hydroxyl," as used herein, refers to -OH.

15 The term "nitro," as used herein, refers to -NO₂.

The term "nitrogen protecting group," as used herein, as used herein refers to groups intended to protect an amino group against undesirable reactions during synthetic procedures. Commonly used N-protecting groups are disclosed in Greene, "Protective Groups In Organic Synthesis," (John Wiley & Sons, New York (1981)). Preferred N-protecting groups are formyl, acetyl, benzoyl, pivaloyl, t-butylacetyl, phenylsulfonyl, 20 benzyl, t-butyloxycarbonyl (Boc), and benzyloxycarbonyl (Cbz).

The term "perfluoroalkyl," as used herein, refers to an alkyl group in which all of the hydrogen atoms have been replaced by fluoride atoms.

25 The term "pharmaceutically acceptable prodrugs," as used herein, represents those prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention.

30 The term "prodrug," as used herein, represents compounds which are rapidly transformed *in vivo* to parent compounds having formula I, for example, by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V. Stella, Prodrugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, and in Edward B. Roche,

ed., *Bioreversible Carriers in Drug Design*, American Pharmaceutical Association and Pergamon Press, 1987, both of which are hereby incorporated by reference. Particularly preferred prodrugs of the invention include compounds having formula I, wherein a nitrogen, hydroxy, or thiol group has attached thereto an aminoacyl, bisaminoacyl (2-mer), or trisaminoacyl (3-mer) group optionally capped with a carboxyl protecting group. The term "aminoacyl," as used herein, refers to a group derived from naturally or unnaturally occurring amino acids. Representative aminoacyl groups include those derived from glycine, alanine, β -alanine, valine, leucine, *iso*-leucine, methionine, serine, threonine, cysteine, phenylalanine, and tyrosine in the racemic, D or L configurations. The terms "bisaminoacyl" and "trisaminoacyl," as used herein, refer to di- and tri- aminoacyl groups, respectively. Representative examples of bisaminoacyl and trisaminoacyl groups include 2-mers and 3-mers derived from glycine, alanine, β -alanine, valine, leucine, *iso*-leucine, methionine, serine, threonine, cysteine, phenylalanine, and tyrosine in the racemic, D or L configurations.

15 The term "pharmaceutically acceptable salt" as used herein refers to salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well-known in the art. For example, S. M. Berge, *et al.* describe pharmaceutically acceptable salts in detail in *J. Pharmaceutical Sciences*, 1977, 66: 1 et seq. The salts may be prepared in situ during the final isolation and purification of the compounds of the invention or separately by reacting a free base function with a suitable acid. Representative acid addition salts include, but are not limited to acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isethionate), lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, phosphate, glutamate, bicarbonate, p-toluenesulfonate and undecanoate. Also, the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl and diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; arylalkyl halides like benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained. Examples of acids which may be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as

hydrochloric acid, hydrobromic acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid.

Basic addition salts can be prepared *in situ* during the final isolation and purification of compounds of this invention by reacting a carboxylic acid-containing moiety with a suitable base such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation or with ammonia or an organic primary, secondary or tertiary amine. Pharmaceutically acceptable salts include, but are not limited to, cations based on alkali metals or alkaline earth metals such as lithium, sodium, potassium, calcium, magnesium and aluminum salts and the like and nontoxic quaternary ammonia and amine cations including ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine and the like. Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, piperazine and the like.

Determination of Biological Activity

Compounds of this invention were tested in a 48-hour cellular proliferation assay that uses human colon adenocarcinoma, MDR positive (HCT-15) cells, and human lung large cell carcinoma, MDR negative (NCI-H460) cells, in the 96-well microtitre format described in Skehan P., et al. New Colorimetric Cytotoxicity Assay for Anticancer Drug Screening. 1990, J. Natl. Cancer Inst. 82:1107-1112, hereby incorporated by reference. Briefly, the wells of a microtitre plate were charged sequentially with cultured cells and compounds of the invention (1.0×10^{-4} to 1.0×10^{-11} M in 10% DMSO prepared by dissolving compounds of the invention in DMSO and adding 11 μ L of the DMSO solution to 100 μ L of culture medium for a final DMSO concentration of 10%). Two of the following controls were also present in each microtitre plate: a solvent (DMSO) control without drug that yielded a 0% inhibition level and a trichloroacetic acid-treated well that yielded a 100% inhibition level. The cells were grown in culture (37 °C, 5% CO₂ atmosphere) for 48 hours then fixed by the addition of trichloroacetic acid. The wells were stained with sulforhodamine, washed with 1% acetic acid, and treated with 0.01M tris buffer (100 μ L) to solubilize the adherent dye. The absorbance of the dye solution was measured with a Molecular Devices SpectraMax340 plate reader. Percent inhibition and Inhibitory Concentrations (IC₅₀) values were obtained by calculating the proportional response of the experimental values to the absorbance values of the controls. These data are shown in Tables 1 and 2.

Table 1
Inhibitory Potency of Representative Compounds

Example Number	NCI-460 (% Inhibition at 10^{-4} M)	HCT-15 (% Inhibition at 10^{-4} M)
1	100	100
2	100	100
3	100	100
4	100	100
5	100	100
6	100	100
7	100	100
8	100	100
9	100	100
10	100	100
11	100	100
12	100	100
13	100	100
14	100	100
15	50	50
16	90.68	96.22
17	85.77	91.05
18	92.18	95.95
19	100	98.89
20	100	90.97
21	92.41	100
22	100	100

Table 2
Inhibitory Potency of Representative Compounds

5

	IC ₅₀ (HCT-15)	IC ₅₀ (NCI-H460)
27	83 nM	170 nM
28	210 nM	390 nM
29	39 nM	60 nM
30	24 nM	28 nM
31	580 nM	470 nM
32	16 μ M	350 μ M
33	32 nM	120 nM
34	650 nM	1500 nM

35	2.4 μ M	3.2 μ M
36	160 μ M	270 μ M
37	44 μ M	37 μ M
38	63 μ M	78 μ M
39	33 nM	68 nM
40	62 nM	82 nM
41	520 nM	590 nM
44	6.6 μ M	3.8 μ M
46	440 nM	470 nM
56	12 μ M	6 μ M
60	280 nM	410 nM
61	1.9 nM	1.8 nM
62	23 nM	37 nM
63	20 nM	43 nM
64	3.96 nM	2.9 nM
65	37 nM	51 nM
66	46 nM	100 nM
67	23 nM	38 nM
68	47 nM	150 nM
69	450 nM	680 nM
70	170 nM	210 nM
71	5 nM	17 nM
72	11 nM	36 nM
73	34 nM	41 nM
74	1.3 μ M	1.2 μ M
75	1.9 μ M	3.8 μ M
76	1.30 μ M	540 μ M
77	3.8 μ M	4.2 μ M
78	1.9 μ M	3.5 μ M

As shown by the data in Table 1 and Table 2, the compounds of the invention, including but not limited to those specified in the examples, are useful for the treatment of diseases caused or exacerbated by cell proliferation. As cell proliferation inhibitors, these compounds are useful in the treatment of both primary and metastatic solid tumors and carcinomas of the breast, colon, rectum, lung, oropharynx, hypopharynx, esophagus, stomach, pancreas, liver, gallbladder, bile ducts, small intestine, urinary tract including

kidney, bladder and urothelium, female genital tract including cervix, uterus, ovaries, choriocarcinoma, and gestational trophoblastic disease, male genital tract including prostate, seminal vesicles, testes, and germ cell tumors, endocrine glands including thyroid, adrenal, and pituitary, skin including hemangiomas, melanomas, sarcomas arising from bone or soft tissues including Kaposi's sarcoma, tumors of the brain, nerves, and eyes, meninges including astrocytomas, gliomas, glioblastomas, retinoblastomas, neuromas, neuroblastomas, Schwannomas and meningiomas, solid tumors arising from hematopoietic malignancies including leukemias and chloromas, plasmacytomas, plaques, tumors of mycosis fungoides, cutaneous T-cell lymphoma/leukemia, lymphomas including Hodgkin's and non-Hodgkin's lymphomas, prophylaxis of autoimmune diseases including rheumatoid, immune and degenerative arthritis, ocular diseases including diabetic retinopathy, retinopathy of prematurity, corneal graft rejection, retrolental fibroplasia, neovascular glaucoma, rubeosis, retinal neovascularization due to macular degeneration, hypoxia, abnormal neovascularization conditions of the eye, skin diseases including psoriasis, blood vessel diseases including hemangiomas and capillary proliferation within atherosclerotic plaques, Osler-Webber Syndrome, myocardial angiogenesis, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma, and wound granulation.

The compounds of the present invention may also be useful for the prevention of metastases from the tumors described above either when used alone or in combination with radiotherapy and/or other chemotherapeutic treatments conventionally administered to patients for treating cancer. For example, when used in the treatment of solid tumors, compounds of the present invention may be administered with chemotherapeutic agents such as alpha interferon, COMP (cyclophosphamide, vincristine, methotrexate, and prednisone), etoposide, mBACOD (methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone), PRO-MACE/MOPP (prednisone, methotrexate (w/leucovorin rescue), doxorubicin, cyclophosphamide, taxol, etoposide/mechlorethamine, vincristine, prednisone, and procarbazine), vincristine, vinblastine, angiostatin, TNP-470, pentosan polysulfate, platelet factor 4, angiostatin, LM-609, SU-101, CM-101, Techgalan, thalidomide, SP-PG, and the like. Other chemotherapeutic agents include alkylating agents such as nitrogen mustards (mechlorethamine, melphalan, chlorambucil, cyclophosphamide and ifosfamide), nitrosoureas including carmustine, lomustine, semustine and streptozocin, alkyl sulfonates including busulfan, triazines including dacarbazine, ethylenimines including thiotepa and hexamethylmelamine, folic acid analogs including methotrexate, pyrimidine analogues including 5-fluorouracil and cytosine arabinoside, purine analogs including 6-mercaptopurine and 6-thioguanine, antitumor antibiotics including actinomycin D, anthracyclines including doxorubicin, bleomycin, mitomycin C and methramycin, hormones

and hormone antagonists including tamoxifen, cortiosteroids and miscellaneous agents including cisplatin and brequinar. For example, a tumor may be treated conventionally with surgery, radiation or chemotherapy and compound of Formula I administration with subsequent compound of Formula I administration to extend the dormancy of micrometastases and to stabilize and inhibit the growth of any residual primary tumor.

Methods of Treatment

The present invention also provides pharmaceutical compositions which comprise compounds of the present invention formulated together with one or more non-toxic pharmaceutically acceptable carriers. The pharmaceutical compositions may be specially formulated for oral administration in solid or liquid form, for parenteral injection, or for rectal administration.

The pharmaceutical compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), buccally, or as an oral or nasal spray. The term "parenteral" administration as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Pharmaceutical compositions of this invention for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

These compositions may also contain adjuvants such as preservative, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.

In some cases, in order to prolong the effect of the drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be

accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form.

Alternatively, delayed absorption of a parenterally administered drug form is

5 accomplished by dissolving or suspending the drug in an oil vehicle.

Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include

10 poly(orthoesters) and poly(anhydrides) Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.

The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid

15 compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.

Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or

20 dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e)

25 solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form

30 may also comprise buffering agents.

Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

The solid dosage forms of tablets, dragees, capsules, pills, and granules can be

35 prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or

preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.

5 The active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned excipients.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as
10 ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.

15 Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan
20 esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, and mixtures thereof.

Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository
25 wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.

Compounds of the present invention can also be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid
30 crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used. The present compositions in liposome form can contain, in addition to a compound of the present invention, stabilizers, preservatives, excipients, and the like. The preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic.

35 Methods to form liposomes are known in the art. See, for example, Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N.Y. (1976), p. 33 et seq.

Dosage forms for topical administration of a compound of this invention include powders, sprays, ointments and inhalants. The active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives, buffers, or propellants which may be required. Ophthalmic formulations, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.

Actual dosage levels of active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active compound(s) that is effective to achieve the desired therapeutic response for a particular patient, compositions, and mode of administration. The selected dosage level will depend upon the activity of the particular compound, the route of administration, the severity of the condition being treated, and the condition and prior medical history of the patient being treated. However, it is within the skill of the art to start doses of the compound at levels lower than required for to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.

Generally dosage levels of about 1 to about 50, more preferably of about 5 to about 20 mg of active compound per kilogram of body weight per day are administered orally to a mammalian patient. If desired, the effective daily dose may be divided into multiple doses for purposes of administration, e.g. two to four separate doses per day.

Synthetic Methods


The compounds and processes of the present invention will be better understood in connection with the following synthetic schemes which illustrate the methods by which the compounds of the invention may be prepared. The compounds of this invention may be prepared by a variety of synthetic routes. Representative procedures are outlined in Scheme 1 where R^A , R^B , R^C , R^D , R^E , and R^2 , are defined previously unless indicated otherwise. Depending on the nature of R^A , R^B , R^C , R^D , R^E , and R^2 , protection and subsequent deprotection of other reactive groups can be required to successfully complete the described synthetic sequences. Commonly used protecting groups are disclosed in Greene, "Protective Groups In Organic Synthesis," (John Wiley & Sons, New York (1981)), which is incorporated herein by reference. It will be readily apparent to one of ordinary skill in the art reviewing the synthetic route depicted below that other compounds within Formula I can be synthesized by the substitution of appropriate reactants and agents in the synthesis shown below.

Abbreviations

Abbreviations which have been used in the descriptions of the schemes and the examples that follow are: THF for tetrahydrofuran; DMF for N,N-dimethylformamide;

EDC for 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; LDA for lithium diisopropylamide; TFA for trifluoroacetic acid; DMSO for dimethylsulfoxide; DMAP for 4-(N,N-dimethylamino)pyridine; HBTU for O-(azabenzotriazole-1-yl)-N,N,N',N'-tetramethyluroniumhexafluorophosphate; Boc for tert-butylcarbonyloxy; DPPA for diphenylphosphoryl azide; DCC for dicyclohexylcarbodiimide; EDC for 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride. Starting materials, reagents and solvents were purchased from Aldrich Chemical Company (Milwaukee, Wi).


10



As shown in Scheme 1, the aldehyde (i) can be treated with trimethylsilylnitrile to provide silyloxynitrile intermediate (ii) which can be treated with reducing agents such as lithium aluminum hydride to provide amino alcohol (iii). Treatment of (iii) with

15 carboxylic acids in the presence of a dehydrating agents such as trifluoromethane sulfonic anhydride and base provides compounds of Formula I. Although the solvents used in these reactions is not particularly limited, a solvent which is little reactive with the starting materials and in which the starting materials are soluble is generally used. Examples of

20 such solvents include pyridine, diisopropylethylamine, triethylamine, THF, dioxane, benzene, toluene, diethyl ether, chloroform, dichloromethane, ethyl acetate, DMF, DMSO, or mixtures thereof. The reactions can be run at room temperature, or at lower or elevated temperatures, as needed. The reaction times are generally 30 minutes to 18 hours and can be arbitrarily selected depending on the types of starting materials and the reaction temperature.



As shown in Scheme 2, treatment of (i) with nitromethane in the presence of base, such sodium or potassium hydroxide, provided hydroxy nitro intermediate (v) which, upon treatment with a reducing agent such as palladium on carbon, provided aminol (iii). Treatment of (iii) with a carboxylic acid in the presence of a dehydrating agent such as EDCI provided amide (vii) which was dehydrated in the presence of methoxycarbonylsulfamoyl)triethylammonium hydroxide to provide compounds of Formula I. Although the solvents used in these reactions is not particularly limited, a solvent which is little reactive with the starting materials and in which the starting materials are soluble is generally used. Examples of such solvents include THF, dioxane, benzene, toluene, diethyl ether, chloroform, dichloromethane, ethyl acetate, or mixtures thereof. The reactions can be run at room temperature, or at lower or elevated temperatures, as needed. The reaction times are generally 30 minutes to 18 hours and can be arbitrarily selected depending on the types of starting materials and the reaction temperature.

The compounds and processes of the present invention will be better understood in connection with the following examples, which are intended as an illustration of and not a limitation upon the scope of the invention.

Example 1

2-(4-dimethylaminophenyl)-5-(3,4,5-trimethoxyphenyl)-Δ^{2,3}-oxazoline

Example 1A

1-(1-hydroxy-2-aminoethyl)-3,4,5-trimethoxy benzene

A solution of 3,4,5-trimethoxybenzaldehyde (10 g, 51 mmol) and nitromethane (10 mL) in ethanol at 0 °C was treated with 10% sodium hydroxide (21.4 mL, 53.5 mmol), stirred for 45 seconds, treated with 2% acetic acid (162 mL), stirred for 1 hour in the ice bath, and filtered. The solid was washed with water and dried under vacuum to provide
5 9.0 g of the desired product as an off-white solid.

Example 1B

2-amino-1-(3,4,5-trimethoxyphenyl)ethanol

Example 1A was reduced with 10% Pd/C in acetic acid under 4 atmospheres for 3
10 hours to provide the desired product as the acetic acid salt.
mp 103-104 °C;
MS (CDI/NH₃) m/z 228 (M+H)⁺;
¹H NMR (300 MHz, CDCl₃) δ 2.08 (s, 3H), 2.82-2.90 (m, 1H), 3.03-3.08 (m, 1H), 3.83
(s, 3H), 3.88 (s, 6H), 4.62-4.67 (m, 1H), 6.60 (s, 2H).

15

Example 1C

1-((1-hydroxy-2-((4-dimethylamino)benzoylamino)ethyl)-3,4,5-trimethoxy benzene

A solution of Example 1B (287 mg) and diisopropylethylamine (2 mL) in dichloromethane (15 mL) at 0 °C was treated slowly with a solution of 4-dimethylamino
20 benzoylchloride (219 mg) in dichloromethane (10 mL), stirred for 18 hours warming to room temperature, and concentrated to near dryness. The concentrate was purified by column chromatography on silica gel with 1:1 hexanes/ethyl acetate to provide 340 mg of the desired product as a white solid.
mp 155-157 °C;
25 MS (CDI/NH₃) m/z 375 (M+H)⁺;
¹H NMR (300 MHz, CDCl₃) δ 3.03 (s, 6H), 3.44-3.57 (m, 1H), 3.83 (s, 9H), 4.02 (bs, 1H), 4.88-4.95 (m, 1H), 6.62 (s, 2H), 6.64 (d, J=7Hz, 2H), 7.66 (d, J=7Hz, 2H).

Example 1D

2-(4-dimethylaminophenyl)-5-(3,4,5-trimethoxyphenyl)-Δ^{2,3}-oxazoline

A solution of Example 1C (320 mg, 0.86 mmol) in chloroform (15 mL) at cooled to -20 °C was treated sequentially with pyridine (0.2 mL) and by triflic anhydride (0.2 mL), stirred for 30 minutes, washed with saturated NaHCO₃ and brine, dried (Na₂SO₄), filtered, and concentrated. The concentrate was purified by flash chromatography on
35 silica gel with 1:1 hexanes/ethyl acetate to provide 220 mg of the desired product as an off-white solid.
MS (DCI/NH₃) m/z 357 (M+H)⁺;

¹H NMR (300 MHz, CDCl₃) δ 3.05 (s, 6H), 3.85 (s, 9H), 3.96 (dd, 1H, J=7Hz), 4.43 (dd, 1H, J=9Hz), 5.57 (t, 1H, J=7Hz), 6.58 (s, 2H), 6.70 (d, 2H, J=8Hz), 7.93 (d, 2H, J=8Hz).

Example 2

5 2-(3-hydroxy-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

Example 20 was hydrolyzed to provide the desired product.

MS (DCI/NH₃) m/z 360 (M+H)⁺;

¹H NMR (CDCl₃) δ 7.61-7.59 (m, 2H), 6.89 (d, 1 H, J=8.5 Hz), 6.56 (s, 2H), 5.77 (bs, 1H), 5.59-5.54 (m, 1H), 4.48-4.39 (m, 1H), 4.02-3.95 (m, 1H), 3.95 (s, 3H), 3.86 (s, 6H),
10 3.84 (s, 3 H).

Example 3

2-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

3, 5-Dimethoxybenzoic acid was processed as described in Example 4 to provide
15 the desired product.

MS (DCI/NH₃) m/z 344 (M+H)⁺;

¹H NMR (CDCl₃) δ 8.06-7.99 (m, 2H), 6.98-6.92 (m, 2H), 6.57 (s, 2H), 5.59 (dd, 1 H, J=9.8, 8.5 Hz), 4.46 (dd, 1 H, J=14.6, 10.2 Hz), 4.00 (dd, 1 H, J=14.6, 8.5 Hz), 3.87 (s, 3H), 3.85 (s, 9 H).

20

Example 4

2-(3,5-dimethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

Example 4A

25 N-(2-hydroxy-2-phenylethyl)-3,5-dimethoxybenzamide

A suspension of 3, 5-dimethoxybenzoic acid (1.00g, 5.49 mmol) in dichloromethane (50 mL) at 0 °C was treated with HOBt hydrate (0.742 g, 5.49 mmol), stirred for 15 minutes, treated with EDCI (1.05 g, 5.49 mmol) in one portion, stirred for an additional 25 minutes, treated with triethylamine (1.84g; 2.53 mL, 1.9 mmol) and the acetate salt of 2-amino-1-(3,4,5-trimethoxyphenyl)ethanol (1.58 g, 005.49 mmol), stirred
30 for 18 hours while warming to room temperature, and concentrated. The concentrate was partitioned between ethyl acetate (400 mL) and water (200 mL), and the organic extract was washed sequentially with 10% KHSO₄ (200 mL), water (100 mL), NaHCO₃ (200 mL), and water (100 mL), dried (MgSO₄), filtered, and concentrated to provide 1.56 g of
35 the desired product as a white foamy semi-solid.

MS (ESI(+)) m/z 392 (M+H)⁺ and 374 (M+H -18)⁺;

¹H NMR; (CDCl₃) δ 3.50 (m, 1H), 3.70-3.80 (overlapping s's; 15H), 3.90 (m, 1H), 4.90 (d of d, J=7.0; 12.0 Hz; 1H), 6.55-6.65 (t, m; and s; J=7.0 Hz; 4H), 6.90 (d, J=3.0 Hz; 2H).

5

Example 4B

2-(3,5-dimethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ^{2,3}-oxazoline

A solution of Example 4A (50 mg, 0.128 mmol) in CHCl₃ (0.50 mL) was treated sequentially with triethylamine (89.5 μL, 65 mg, 0.64 mmol) and methanesulfonyl chloride (15.6 mg., 10.7 μL, 0.138 mmol), heated at reflux for 48 hours, cooled to room temperature, treated with CHCl₃ (1.0 mL) and water (0.200 mL), heated to reflux for 1 hour, cooled to room temperature; diluted with CHCl₃ (3.0 mL), washed sequentially with water (2×3 mL), 10% NaHCO₃ (3 mL), water (3 mL), and brine (3 mL), dried (Na₂SO₄), filtered and concentrated. The concentrate was purified by elution with a solution of 9:1 hexanes/acetone from a 2.00 g silica gel Analtech Sep-pak® cartridge to provide 10 mg of the desired product.

MS (APCI(+)) m/z 374 (M+H)⁺ and (APCI(-)) m/z 372 (M-H)⁻;

¹H NMR (CDCl₃) δ 3.80-3.90 (overlapping s; 15H), 4.01 (dd, J=8.4, 14.9 Hz; 1H), 4.47 (dd, J=8.4, 14.9 Hz; 1H), 5.59 (ps t, J=10.1 Hz; 1H), 6.55 (s, 2H), 6.62 (t, J=7.0 Hz; 1H), 7.35 (d, J=3.0 Hz; 2H). ¹H NMR purity was greater than or equal to 95%.

20

Example 5

2-(3-acetylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)-Δ^{2,3}-oxazoline

A solution of Example 11 (50 mg, 0.142 mmol) in dichloromethane at room temperature was treated sequentially with triethylamine (0.5 mL), DMAP (5 mg), and acetic anhydride (0.5 mL, excess), stirred at room temperature for 3 hour, and concentrated. The concentrate was purified by flash on silica gel with 1:1 hexanes/ethyl acetate to provide 25 mg of the desired product as an off-white solid.

MS (DCI/NH₃) m/z 395 (M+H)⁺;

¹H NMR (300 MHz, CDCl₃) δ 2.68 (s, 3H), 3.86 (s, 9H), 4.15 (brm, 1H), 4.55 (brm, 1H), 5.77 (brm, 1H), 6.60 (s, 2H), 6.76 (d, J=4.2 Hz, 1H), 7.52 (d, J=4.2 Hz, 1H), 8.12 (d, J=9.0 Hz, 1H), 8.55 (d, J=9.0 Hz, 1H).

30

Example 6

2-(1-methylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)-Δ^{2,3}-oxazoline

A mixture of crushed KOH (64 mg, 1.14 mmol) in DMSO (1 mL) was stirred at room temperature for 5 minutes then treated with Example 11 (40 mg, 0.114 mmol),

35

stirred for 45 minutes, treated with methyl iodide, (14.4 μ L, 0.23 mmol), stirred for 24 hours, treated with water, and extracted with ethyl acetate (2 \times 10 mL). The extract was washed with water and brine, dried (Na₂SO₄), and concentrated. The concentrate was purified by flash column chromatography on silica gel to provide 20 mg of the desired product.

MS (DCI/NH₃) m/z 367 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 3.65 (s, 3H), 3.75 (s, 6H), 3.83 (s, 3H), 3.86 (dd, J=8.4, 15.0 Hz, 1H), 4.37 (dd, J=9.9, 15.0 Hz, 1H), 5.67 (dd, J=8.4, 9.9 Hz, 1H), 6.55 (d, J=3.3 Hz, 1H), 6.69 (s, 2H), 7.42 (d, J=3.3 Hz, 1H), 7.53 (d, J=8.7 Hz, 1H), 7.78 (dd, J=1.5, 9.0 Hz, 1H), 8.16 (s, 1H).

Example 7

2-(indol-3-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline

3-Indolecarboxylic acid was processed as described in Example 11 to provide the desired product.

MS (DCI/NH₃) m/z 353 (M+H)⁺;

¹H NMR (300 MHz, CDCl₃) δ 3.85 (s, 6H), 3.86 (s, 3H), 4.04 (dd, J=8.4, 15.0 Hz, 1H), 4.51 (dd, J=9.9, 15.0 Hz, 1H), 5.56 (dd, J=8.4, 9.9 Hz, 1H), 6.62 (s, 2H), 7.24-7.33 (m, 2H), 7.45 (m, 1H), 7.92 (brs, 1H), 8.26 (m, 1H), 8.70 (brs, 1H).

Example 8

2-(indol-2-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline

2-Indolecarboxylic acid was processed as described in Example 11 to provide the desired product.

MS (DCI/NH₃) m/z 353 (M+H)⁺;

¹H NMR (300 MHz, CDCl₃) δ 3.86 (s, 9H), 4.03 (dd, J=8.4, 15.0 Hz, 1H), 4.49 (dd, J=9.9, 15.0 Hz, 1H), 5.65 (dd, J=8.4, 9.9 Hz, 1H), 6.58 (s, 2H), 7.12-7.18 (m, 2H), 7.29 (td, J=0.9, 7.5 Hz, 1H), 7.40 (d, J=7.5 Hz, 1H), 7.68 (d, J=7.5 Hz, 1H), 9.33 (brs, 1H).

Example 9

2-(1-methoxymethylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline

Example 11 was processed as described in Example 6 (substituting chloromethyl methyl ether for methyl iodide) to provide the desired product.

MS (DCI/NH₃) m/z 397 (M+H)⁺;

¹H NMR (300 MHz, CDCl₃) δ 3.26 (s, 3H), 3.86 (s, 9H), 4.08 (brm, 1H), 4.52 (brm, 1H), 5.47 (s, 2H), 5.68 (brm, 1H), 6.57-6.67 (m, 3H), 7.24 (m, 1H), 7.54 (brm, 1H), 8.02 (brm, 1H), 8.41 (brm, 1H).

Example 102-(4-amino-3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

5

Example 10A2-(4-nitro-3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

4-Nitro-3-methoxybenzoic acid was processed as described for 5-indolecarboxylic acid in Example 11 to provide the desired product.

10

Example 10B2-(4-amino-3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

A solution of Example 10A (90 mg, 0.23 mmol) in a mixture of 1:1 THF/H₂O (2 mL) was treated with excess K₂CO₃ and Na₂S₂O₄, stirred at room temperature for 18 hours, treated with water, and extracted with ethyl acetate. The extract was washed with
15 brine and dried (Na₂SO₄), filtered, and concentrated. The concentrate was purified by preparative thin layer chromatography to provide 12 mg of the desired product.

MS (DCI/NH₃) m/z 359 (M+H)⁺;

¹H NMR (300 MHz, CDCl₃) δ 3.84 (s, 3H), 3.86 (s, 6H), 3.94 (s, 3H), 4.00 (dd, J=8.7, 15.0 Hz, 1H), 4.45 (dd, J=9.6, 15.0 Hz, 1H), 5.59 (dd, J=8.7, 9.6 Hz, 1H), 6.58 (s, 2H),
20 6.70 (d, J=8.1 Hz, 1H), 7.51 (d, J=9.0 Hz, 1H), 7.58 (brs, 1H).

Example 112-(indol-5-yl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

25

Example 11AN-(hydroxy(3,4,5-trimethoxyphenyl)methyl)-1H-indole-5-carboxamide

A solution of 5-indolecarboxylic acid (2.0 g, 12.4 mmol) in DMF (25 mL) at room temperature was treated portionwise with 1, 1'-carbonyldiimidazole (2.1g, 13.0 mmol). In a separate reaction, a suspension of β-hydroxyamine acetic acid salt (3.92g, 13.7 mmol) in
30 DMF (20 mL) was treated with diisopropylethylamine (5.0 mL, 28.7 mmol) and DMAP (30.3 mg, 0.25 mmol). When the suspension of β-hydroxyamine vanished, the imidazolide solution was transferred dropwise to the β-hydroxyamine solution. The pink solution was stirred at room temperature for 3 hours, treated with water (100 mL), and adjusted to pH 5.5 with 3N HCl to cause precipitation of white solid. The solid was
35 filtered, washed with cold water and dried in a vacuum oven to provide 3.7 g of the desired product as a white solid.

Example 11B(5R) 2-(indol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline

A solution of Example 11A (200 mg, 0.54 mmol) in THF (10 mL) was treated with Burgess Reagent (142 mg, 0.60 mmol), refluxed 1 hour, cooled, and partitioned
5 between ethyl acetate and brine. The organic layer was dried (Na_2SO_4), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 1:1 hexanes/ethyl acetate to provide 120 mg of the desired product as a light yellow solid.

MS (DCI/ NH_3) m/z 353 ($\text{M}+\text{H}$)⁺;

10 ¹H NMR (300 MHz, CDCl_3) δ 3.86 (s, 9H), 4.04 (dd, J=8.7, 15.0 Hz, 1H), 4.50 (dd, J=9.9, 15.0 Hz, 1H), 5.63 (dd, J=8.7, 9.9 Hz, 1H), 6.61 (s, 2H), 6.64 (m, 1H), 7.28 (t, J=3.0 Hz, 1H), 7.46 (d, J=9.7 Hz, 1H), 7.95 (dd, J=1.8, 9.7 Hz, 1H), 8.37 (s, 1H), 8.43 (brs, 1H).

Example 122-(4-amino-3-methylphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline

4-amino-3-methylbenzoic acid was processed as described for 5-indolecarboxylic acid in Example 11 to provide the desired product.

MS (DCI/ NH_3) m/z 343 ($\text{M}+\text{H}$)⁺;

20 ¹H NMR (300 MHz, CDCl_3) δ 2.19 (s, 3H), 3.84 (s, 9H), 3.95 (dd, J=8.7, 15.0 Hz, 1H), 4.41 (dd, J=9.9, 15.0 Hz, 1H), 5.53 (dd, J=8.7, 9.9 Hz, 1H), 6.57 (s, 2H), 6.68 (d, J=8.7 Hz, 1H), 7.69-7.77 (m, 2H);

Anal. calcd for $\text{C}_{19}\text{H}_{22}\text{N}_2\text{O}_4 \cdot 0.10\text{CH}_3\text{C}(\text{O})\text{OCH}_2\text{CH}_3$: C, 66.35; H, 6.54; N, 7.98. Found: C, 66.56; H, 6.57; N, 7.70.

25 Using the procedures described herein, Examples 13-15 were prepared.

Example 132-(3-hydroxy-4-methoxyphenyl)-4-dimethyl-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline

30 MS (DCI/ NH_3) m/z 372 ($\text{M}+\text{H}$)⁺;

¹H NMR (CDCl_3) δ 7.91-7.88 (m, 2H), 6.71-6.67 (m, 2H), 6.52 (s, 2H), 5.16 (s, 1H), 3.85 (s, 3H), 3.84 (s, 6H), 3.03 (s, 6H), 1.53 (s, 3H), 0.88 (s, 3H).

Example 142-(N-methyl-tetrahydroquinol-6-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline

35 MS (DCI/ NH_3) m/z 383 ($\text{M}+\text{H}$)⁺;

¹H NMR (CDCl₃) δ 7.87-7.83 (m, 1H), 7.73-7.69 (m, 1H), 6.57-6.53 (m, 3H), 5.63-5.58 (m, 1H), 4.48-4.40 (m, 1H), 4.04-3.97 (m, 1H), 3.85 (s, 9H), 3.37-3.33 (m, 2H), 2.98 (s, 3H), 2.81-2.77 (m, 2H), 2.01-1.94 (m, 2H).

5

Example 152-(2-methyl-cyclopropyl)-5-(3,4,5-trimethoxyphenyl)-Δ^{2,3}-oxazoline

MS (DCI/NH₃) m/z 292 (M+H)⁺;

¹H NMR (CDCl₃) δ 6.62 (s, 2H), 5.93-5.90 (m, 1H), 4.99-4.94 (m, 1H), 3.87 (s, 6H), 3.85 (s, 3H), 3.64-3.50 (m, 1H), 1.61 (bs, 1H), 1.42-1.05 (m, 5H), 0.63-0.58 (m, 1H).

10

Example 162-(4-ethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ^{2,3}-oxazolineExample 16A

15

4-ethoxy-N-[2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]benzamide

4-Ethoxybenzoic acid was processed as described in Example 4 to provide the desired product. HPLC retention time: 4.3 minutes with 1:4 acetonitrile/aqueous ammonium acetate and 10 minutes with 95:5 acetonitrile/aqueous ammonium acetate. (APCI(+)) m/z 376 (M+H)⁺ and 358 (M+H-18)⁺.

20

Example 16B2-(4-ethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ^{2,3}-oxazoline

A solution of Example 16A in THF was treated with treated with (methoxycarbonylsulfamoyl)triethylammonium hydroxide (Burgess Reagent, 1.1 equivalents) in THF, heated at 70 °C for three days, cooled, and concentrated. The residue was purified by preparative reverse phase HPLC to provide the desired product. HPLC retention time: 6.57 minutes using the HPLC gradient system described in Example 16A.

MS (APCI(+)) m/z 358 (M+H)⁺.

30

Example 172-(3,4-dimethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ^{2,3}-oxazoline

35

Example 17AN-(2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl)-3,4-dimethoxybenzamide

3,4-Dimethoxybenzoic acid was processed as described in Example 4 to provide the desired product. HPLC retention time: 3.5 minutes using the conditions described in Example 16A.

MS (APCI(+)) m/z 392 (M+H)⁺ and 374 (M+H-18)⁺.

5

Example 17B

2-(3,4-dimethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ^{2,3}-oxazoline

Example 17A was processed as described in Example 16 to provide the desired product. HPLC retention time: 5.72 minutes using conditions as described in Example 16A.

10

MS (APCI(+)) m/z 374 (M+H)⁺.

Example 18

2-(4-benzyloxy-3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ^{2,3}-oxazoline

15

Example 18A

4-(benzyloxy)-N-[2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-3-methoxybenzamide

20

4-Benzyloxy-3-methoxybenzoic acid was processed as described in Example 4 to provide the desired product. HPLC retention time: 4.6 minutes using the conditions described in Example 16A.

MS (APCI(+)) 468 (M+H)⁺ and 450 (M+H-18).

Example 18B

25

2-(4-benzyloxy-3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ^{2,3}-oxazoline

Example 18A was processed as described in Example 16 to provide the desired product. HPLC retention time: 7.07 minutes using conditions as described in Example 16A.

MS (APCI(+)) 450 (M+H)⁺.

30

Example 19

2-(2,3-dihydro-5-bromo-7-benzofuranyl)-5-(3,4,5-trimethoxyphenyl)-Δ^{2,3}-oxazoline

Example 19A

5-bromo-N-(2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl)-2,3-dihydro-1-benzofuran-7-

35

2, 3-Dihydrobenzofuran-5-bromo-7-carboxylic acid was processed as described in Example 4 to provide the desired product. HPLC retention time: 4.5 minutes using the conditions described in Example 16A.

MS (APCI(+)) m/z 454 (M+H)⁺ and 436 (M+H-18)⁺.

Example 19B

2-(2,3-dihydro-5-bromo-7-benzofuranyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

5 Example 19A was processed as described in Example 16 to provide the desired product. HPLC retention time: 6.65 minutes using the conditions described in Example 16A.

MS (APCI(+)) m/z 436 (M+H)⁺.

Example 20

2-(3-acetoxy-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

Example 20A

5-(((2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl)amino))carbonyl)-2-methoxyphenyl

15 A solution of 3-acetoxy-4-methoxybenzoic acid 392 mg, 1.86 mmol) in dichloromethane (10 mL) and DMF (1 drop) at 0 °C was treated with oxalyl chloride (0.33 mL), warmed to room temperature, stirred for 1 hour, and concentrated. The concentrate was dissolved in toluene and concentrated to provide a yellow solid. This concentrate was dissolved in pyridine (5 mL), cooled to 0 °C and treated with 2-amino-1-
20 (3,4,5-trimethoxyphenyl)ethanol, acetic acid salt (536 mg, 1.86 mmol), stirred for 18 hours while warming to room temperature, diluted with ethyl acetate, and washed sequentially with 1M sodium bisulfate (2×), water (1×), 10% NaHCO₃, and brine, dried (MgSO₄), filtered, and concentrated to provide 297 mg of the desired product.

MS (ESI(+)) m/z 420 (M+H)⁺;

25 ¹H NMR (300 MHz, CDCl₃) δ 7.66 (dd, J=2.2, 8.5, 1H), 7.49 (d, J=2.2, 1H), 7.00 (d, J=8.5, 1H), 6.63 (s, 2H), 6.45 (m, 1H), 4.90 (m, 1H), 3.9 (m, 1H), 3.89 (s, 3H), 3.86 (s, 6H), 3.84 (s, 3H), 3.51 (m, 1H), 2.33 (s, 3H).

Example 20B

2-(3-acetoxy-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

30 A solution of Example 20A (290 mg, 0.69 mmol) in chloroform (10 mL) at 0 °C was treated with thionyl chloride (0.1 mL, 1.38 mmol), stirred for 40 minutes, warmed to room temperature, stirred for 1 hour, poured into 10% NaHCO₃, and extracted with dichloromethane (2×). The extracts were dried (MgSO₄), filtered, and concentrated. The
35 concentrate was purified by flash chromatography on silica gel with 1:1 hexanes/ethyl acetate to provide 137 mg of the desired product as an off-white solid.

MS (DCI/NH₃) m/z 402 (M+H)⁺;

¹H NMR (300 MHz, CDCl₃) δ 7.64 (dd, J=2.0, 8.5, 1H), 7.47 (d, J=2.0, 1H), 7.00 (d, J=8.5, 1H), 6.65 (s, 2H), 6.37 (m, 1H), 5.07 (dd, J=5.4, 8.8, 1H), 4.07 (m, 1H), 3.88 (s, 3H), 3.86 (s, 6H), 3.85 (s, 3H), 3.76 (m, 1H), 2.33 (s, 3H).

5

Example 212-(1-methyl-2,3-dihydro-indol-5-yl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazolineExample 21A1-methyl-2, 3-dihydro-indole-5-carboxylic acid (N-[2-hydroxy-2-(3,4,5-trimethoxyphenyl) ethyl]) amide

10

A suspension of indole-5-carboxylic acid, (N-[2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]) amide (207 mg, 0.56 mmol) and paraformaldehyde (168 mg, 5.6 mmol) in acetic acid (5 mL) was treated with sodium cyanoborohydride (176 mg, 2.79 mmol), stirred for 18 hours, and concentrated. The concentrate was partitioned between ethyl acetate and 10% NaHCO₃, washed sequentially with 10% NaHCO₃ and brine, dried

15

(MgSO₄), filtered, and concentrated to provide 218 mg of the desired product.

MS (ESI(+)) m/z 387 (M+H)⁺;

¹H NMR (300 MHz, CDCl₃) δ 7.51 (m, 2H), 6.63 (s, 2H), 6.38 (d, J=8.1, 1H), 4.90 (m, 1H), 3.85 (m, 10H), 3.5 (m, 1H), 3.45 (t, J=8.5, 2H), 3.14 (s, 1H), 2.99 (t, J=8.5, 2H),

20

2.82 (s, 3H).

Example 21B2-(1-methyl-2,3-dihydro-indol-5-yl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

A solution of Example 21A (151 mg, 0.39 mmol) in THF (5 mL) was treated with Burgess' Reagent (102 mg, 0.43 mmol), heated to reflux for 1.5 hours, cooled, poured into 10% NaHCO₃ and extracted twice with dichloromethane. The extracts were dried (MgSO₄), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 1:1 ethyl acetate/hexanes to provide 25 mg of the desired product.

25

MS (DCI/NH₃) m/z 369 (M+H)⁺;

¹H NMR (300 MHz, CDCl₃) δ 7.92 (dd, J=1.7, 8.5, 1H), 7.73 (d, J=1.4, 1H), 6.58 (s, 2H), 6.38 (d, J=8.5, 2H), 5.70 (app t, J=9.2, 1H), 4.53 (dd, J=10.2, 13.2, 1H), 4.22 (dd, J=8.5, 12.9, 1H), 3.88 (s, 6H), 3.86 (s, 3H), 3.59 (t, J=8.5, 2H), 3.06 (t, J=8.5, 2H), 2.90 (s, 3H).

35

Example 222-(1-methylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline, hydrochloride

A solution of Example 6 (848 mg, 2.31 mmol) in a mixture of dioxane (15 mL), ether (15 mL), and dichloromethane (5 mL) was treated with 4M HCl in dioxane (0.6 mL, 2.4 mmol) to form a precipitate. The suspension was diluted with hexanes, cooled to 5 °C, and filtered to provide 635 mg of the desired product.

5 ¹H NMR (300 MHz, CD₃OD) δ 8.48 (d, J=1.4, 1H), 7.90 (dd, J=1.7, 8.8, 1H), 7.69 (d, J=8.8, 1H), 7.46 (d, J=3.4, 1H), 6.93 (s, 2H), 6.74 (dd, J=0.7, 3.1, 1H), 6.40 (dd, J=9.8, 10.2, 1H), 4.67 (dd, J=10.2, 11.9, 1H), 4.31 (dd, J=9.8, 11.9, 1H), 3.91 (s, 3H), 3.87 (s, 6H), 3.79 (s, 3H);
Anal. calcd for C₂₁H₂₃ClN₂O₄: C, 62.61 H, 5.75; N, 6.95. Found: C, 62.86; H, 5.76; N, 6.95.
10

Example 23

(5S)-2-(1-methylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)-Δ^{2,3}-oxazoline

Example 23A

3,4,5-trimethoxystyrene

15 A suspension of methyltriphenylphosphonium bromide (86 g, 241 mmol) in THF (250 mL) was treated with 2.5M n-butyllithium in hexanes (96 mL, 240 mmol), stirred for 30 minutes, treated with 3,4,5-trimethoxybenzaldehyde (43 g, 219 mmol) stirred at room temperature for 1 hour, treated with water, and extracted with diethyl ether. The extract
20 was washed with brine, dried (MgSO₄), filtered, and concentrated. The concentrate was purified by Kugelrohr distillation (130 °C at 1 mm Hg) to provide 27.2 g (64%) of the desired product as a colorless oil.

Example 23B

(1S)-2-hydroxy-1-(3,4,5-trimethoxyphenyl)ethanol

25 A mechanically stirred solution of AD-mix-α (50 g) in 1:1 tert-butanol:water (60 mL) at 0 °C was treated dropwise with 3,4,5-trimethoxystyrene (7.5 g, 38.6 mmol), stirred at 0 °C for 3 hours and at room temperature for 18 hours, treated with Na₂SO₃ (50 g),
30 stirred for 30 minutes, diluted with water, and extracted with ethyl acetate (3×). The combined extracts were washed with water (1×) and brine (1×), dried (MgSO₄), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 40:60:4 hexane/ethyl acetate/methanol to provide 5.7 g (65%) of the desired product as a colorless oil that solidified upon standing.

35 $[\alpha]_D^{24} = +34.9^\circ$ (c 2.09, CHCl₃);

Lit. $[\alpha]_D = +36.92^\circ$ (c 2.13, CHCl₃). (Tet. Asym., 1996, 7(4) 1101-1104).

Example 23C(1S)-2-(4-methylbenzenesulfonyloxy)-1-(3,4,5-trimethoxyphenyl)ethanol

A solution of Example 23B (460 mg, 2.0 mmol) in pyridine (2 mL) at 0 °C was treated with para-toluenesulfonyl chloride (384 mg; 2.0 mmol), stirred at 0 °C for 2 hours, treated with 10% HCl, and extracted with diethyl ether. The extract was washed with water (2×) and brine (1×), dried (MgSO₄), filtered, and concentrated to provide 470 mg (61%) of the desired product as a colorless oil which was used in the next step without further purification.

Example 23D(1S)-2-azido-1-(3,4,5-trimethoxyphenyl)ethanol

A solution/slurry of Example 23C (450 mg; 1.2 mmol) and sodium azide (153 mg; 2.4 mmol) in DMF (5 mL) was heated at 80-90 °C for 2 hours, treated with brine, and extracted with ethyl acetate. The extract was washed with brine (2×), dried (MgSO₄), filtered, and concentrated. The concentrate was purified by flash chromatography on silica gel with 30% ethyl acetate/hexane) to provide 223 mg (75%) the desired product as a nearly colorless oil.

Example 23E(1S)-2-amino-1-(3,4,5-trimethoxyphenyl)ethanol

A mixture of Example 23D (253 mg; 1.0 mmol) and 10% Pd/C (50 mg) in ethanol (7 mL) was stirred for 18 hours under hydrogen (balloon), filtered through diatomaceous earth (Celite®), and concentrated. The concentrate was redissolved in ethanol, filtered again through diatomaceous earth, and concentrated to provide 216 mg (95%) of the desired product as an off-white solid which was used in the next step without further purification.

$$[\alpha]_D^{24} = +38.0^\circ (c\ 1.51, \text{CHCl}_3).$$

Example 23F(5S)-2-(1-methylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)-Δ^{2,3}-oxazoline

A suspension of Example 23E (3.41 g, 15.0 mmol), N-methyl-5-cyanoindole (3.75 g, 24.0 mmol) K₂CO₃ (320 mg, 2.3 mmol) in mixture of ethylene glycol (4.8 mL) and glycerol (2.6 mL) was heated to 140 °C under nitrogen for 40 hours, cooled to room temperature, treated with dichloromethane, washed sequentially with water and brine, dried (MgSO₄), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 60:40 ethyl acetate/hexane to provide 3.72 g (68%) of the desired product as white solid.

$$[\alpha]_D^{24} = +195.7^\circ (c\ 1.04, \text{CH}_2\text{Cl}_2);$$

MS (DCI/NH₃) m/z 367 (M+H)⁺;

¹H NMR (CDCl₃) δ 8.34 (d, J=3.0 Hz, 1H), 7.94 (dd, J=3.0, 12.0 Hz, 1H), 7.38 (d, J=9.0 Hz, 1H), 7.12 (d, J=6.0 Hz, 1H), 6.62 (s, 2H), 6.57 (d, J=3.0 Hz, 1H), 5.62 (dd, J=9.0, 12.0 Hz, 1H), 4.48 (dd, J=9.0, 12.0, 1H), 4.02 (m, 1H), 3.86 (s, 6H), 3.85 (s, 3H).

5

Example 24

(5S)-2-(1-methylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline hydrochloride

A solution of of Example 23 (3.73 g, 10.2 mmol) in dichloromethane (67 mL) and diethyl ether (67 mL) was treated with 4M HCl in dioxane (2.8 mL), stirred for 30 minutes, treated with diethyl ether (200 mL), and cooled in a refrigerator for 20 minutes. The resulting precipitate was filtered, washed with ether, and dried under vacuum to provide 3.8 g (93%) of the desired compound as a white solid.
[α]_D²⁴ = + 42.7° (c 0.995, CH₃OH).

15

Example 25

(5R)-2-(1-methylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

Example 23A and AD-mix-β were processed as described in Example 23B to provide the desired product as white solid.

[α]_D²⁴ = -184.5° (c 1.04, CH₂Cl₂);

20 MS (DCI/NH₃) m/z 367 (M+H)⁺;

¹H NMR (CDCl₃) δ 8.32 (d, J=3.0 Hz, 1H), 7.93 (dd, J=3.0, 12.0 Hz, 1H), 7.38 (d, J=9.0 Hz, 1H), 7.12 (d, J=6.0 Hz, 1H), 6.62 (s, 2H), 6.57 (d, J=3.0 Hz, 1H), 5.59 (dd, J=9.0, 12.0 Hz, 1H), 4.48 (dd, J=9.0, 12.0, 1H), 4.00 (m, 1H), 3.86 (s, 6H), 3.85 (s, 3H).

25

The appropriately substituted acids or nitriles were processed as described in Example 6, Example 11, or Example 23, to prepare the following compounds:

Example 26

2-(1-ethylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

30 MS (ESI(+)) m/z 381 (M+H)⁺;

¹H NMR (CDCl₃) δ 8.35 (s, 1H), 7.97 (m, 1H), 7.45 (dd, J=12. 1H), 7.18 (d, J=3.0 Hz, 1H), 6.61 (s, 2H), 6.58 (d, J=3.0 Hz, 1H), 5.65 (br s, 1H), 4.50 (br s, 1H), 4.20 (q, J=7.0 Hz, 2H), 4.05 (br s, 1H), 3.85 (s, 9H), 1.5 (t, J=7 Hz, 3H).

35

Example 27

2-(6-indolyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

MS (ESI(+)) m/z 353 (M+H)⁺;

¹H NMR (CDCl₃) δ 8.53 (br s, 1H), 8.3 (br s, 1H), 7.8 (m, 1H), 7.7 (m, 1H), 7.38 (d, J=3.0 Hz, 1H), 6.60 (m, 1H), 5.66 (br s, 1H), 4.5 (br s, 1H), 4.05 (br s, 1H), 4.10 (br s, 1H), 3.85 (s, 9H).

5

Example 282-(1-methylindol-6-yl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

MS (ESI(+)) m/z 367 (M+H)⁺;

¹H NMR (CDCl₃) δ 8.18 (br s, 1H), 7.79 (d, J=9.0 Hz, 1H), 7.65 (d, J=9.0 Hz, 1H), 7.18 (d, J=4.0 Hz, 1H), 6.60 (s, 2H), 6.52 (d, J=4.0 Hz, 1H), 5.65 (br s, 1H), 4.50 (br s, 1H), 4.05 (br s, 1H), 4.10 (br s, 1H), 3.85 (s, 9H).

10

Example 292-(4-indolyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

MS (ESI(+)) m/z 353 (M+H)⁺;

¹H NMR (CDCl₃) δ 8.38 (br s, 1H), 7.88 (d, J=9.0 Hz, 1H), 7.55 (d, J=9.0 Hz, 1H), 7.25-7.35 (m, 2H), 6.62 (s, 2H), 5.62 (m, 1H), 4.55 (m, 1H), 4.15 (m, 1H), 3.86 (s, 3H), 3.84 (s, 6H).

15

Example 302-(1-methylindol-4-yl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

MS (ESI(+)) m/z 367 (M+H)⁺;

¹H NMR (CDCl₃) δ 7.84 (d, J=9.0 Hz, 1H), 7.50 (d, J=9.0 Hz, 1H), 7.28 (m, 1H), 7.18 (m, 2H), 6.62 (s, 2H), 5.62 (dd, J=9.0, 12.0 Hz, 1H), 4.55 (dd, J=12.0, 15.0 Hz, 1H), 4.08 (dd, J=9.0, 15.0 Hz, 1H), 3.85 (s, 3H), 3.83 (s, 6H).

25

Example 312-(7-indolyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

MS (ESI(+)) m/z 353 (M+H)⁺;

¹H NMR (CDCl₃) δ 10.38 (br, 1H), 7.79 (dd, J=9.0, 15.0 Hz, 1H), 7.32 (t, J=3.0 Hz, 1H), 7.15 (t, J=9.0 Hz, 1H), 6.61 (m, 1H), 6.60 (s, 2H), 5.62 (dd, J=9.0, 12.0 Hz, 1H), 4.55 (dd, J=12.0, 15.0 Hz, 1H), 4.05 (dd, J=9.0, 15.0 Hz, 1H), 3.85 (s, 9H).

30

Example 322-(1-methylindol-7-yl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

MS (ESI(+)) m/z 367 (M+H)⁺;

35

¹H NMR (CDCl₃) δ 7.73 (d, J=9.0 Hz, 1H), 7.61 (d, J=3.0 Hz, 1H), 7.11 (t, J=7.0 Hz, 1H), 7.05 (d, J=6.0 Hz, 1H), 6.60 (s, 2H), 6.55 (d, J=3.0, 1H), 5.65 (m, 1H), 4.50 (m, 1H), 4.09 (m, 1H), 3.93 (s, 3H), 3.86 (s, 6H), 3.85 (s, 3H).

5

Example 332-(1-methylindol-3-yl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

MS (ESI(+)) m/z 367 (M+H)⁺;

¹H NMR (CDCl₃) δ 8.24 (m, 1H), 7.8 (m, 1H), 7.40-7.25 (m, 3H), 6.61 (s, 2H), 5.58-5.52 (m, 1H), 4.50 (dd, J=9.8, 14.2 Hz, 1H), 4.03 (dd, J=8.1, 14.2 Hz, 1H), 3.86 (s, 3H), 3.85 (s, 3H), 3.84 (s, 6H);

10

Anal. calcd for C₂₁H₂₂N₂O₄: C, 68.84; H, 6.05; N, 7.65. Found: C, 68.56; H, 6.07; N, 7.68.

Example 34

15

2-(1-methyl-indol-2-yl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

¹H NMR (CDCl₃) δ 7.69 (d, J=8.1 Hz, 1H), 7.42-7.31 (m, 3H), 6.59 (s, 2H), 5.60 (m, 1H), 4.54 (m, 1H), 4.16 (s, 3H), 4.13-4.06 (m, 1H), 3.86 (s, 6H), 3.85 (s, 3H);

HRMS (FAB) Calc. (M+H)⁺ for C₂₁H₂₃N₂O₄: 367.1658. Found: 367.1663.

20

Example 352-(6-quinolinyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

MS (ESI(+)) m/z 365 (M+H)⁺;

¹H NMR (CDCl₃) δ 9.10 (br s, 1H), 8.55 (br s, 1H), 8.20-8.53 (m, 3H), 7.50 (br s, 1H), 6.60 (d, J=3.0 Hz, 1H), 7.11 (t, 1H), 7.50 (d, J=6.0 Hz, 1H), 6.60 (s, 2H), 5.68 (br s, 1H), 4.85 (br s, 1H), 4.10 (br s, 1H), 3.86 (s, 9H).

25

Example 362-(3-quinolinyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

MS (ESI(+)) m/z 365 (M+H)⁺;

¹H NMR (CDCl₃) δ 9.52 (br s, 1H), 8.78 (br s, 1H), 8.20 (br d, J=9.0 Hz, 3H), 7.92 (d, J=9.0 Hz, 1H), 7.85 (t, J=7.0 Hz, 1H), 7.62 (t, J=7.0 Hz, 1H), 6.60 (s, 2H), 5.65 (m, 1H), 4.55 (m, 1H), 4.10 (m, 1H), 3.87 (s, 9H).

30

Example 372-(4-quinolinyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

MS (ESI(+)) m/z 365 (M+H)⁺;

35

¹H NMR (CDCl₃) δ 9.25 (br s, 1H), 9.05 (br s, 1H), 8.05 (br s, 1H), 8.70-7.90 (m, 2H), 6.60 (s, 2H), 5.67 (m, 1H), 4.70 (m, 1H), 4.23 (m, 1H), 3.88 (s, 9H).

Example 38

5 2-(1-isoquinolinyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

MS (ESI(+)) m/z 365 (M+H)⁺;

¹H NMR (CDCl₃) δ 9.21 (d, J=9.0 Hz, 1H), 8.68 (d, J=6.0 Hz, 1H), 7.68-7.92 (m, 4H), 6.68 (s, 2H), 5.73 (m, 1H), 4.68 (m, 1H), 4.28 (dd, J=9.0, 15.0 Hz, 1H), 3.86 (s, 6H), 3.84 (s, 3H).

10

Example 39

2-(3-amino-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

Example 39A

15 3-(9-fluorenylmethoxycarbonyl)amino-4-methoxybenzoic acid

A suspension of 3-amino-4-methoxybenzoic acid (1.00 g, 6.0 mmol) in acetone (15 mL) was treated portionwise and alternately with Fmoc-succinimide (2.63 g, 7.8 mmol) in acetone (15 mL) and saturated aqueous NaHCO₃ to keep the pH of the solution between 8-9, stirred at room temperature for 18 hours, treated with 3M HCl, and filtered.

20 The solid was washed sequentially with water and dichloromethane and dried under vacuum to provide 1.54 g (66%) of the desired product.

¹H NMR (DMSO-d₆) δ 8.91 (s, 1H), 8.23 (br s, 1H), 7.93 (d, J=9.0 Hz, 2H), 7.7 (m, 3H), 7.45 (t, J=7.0 Hz, 2H), 7.35 (t, J=7.0 Hz, 2H), 7.14 (d, J=9.0 Hz, 1H), 4.25-4.42 (m, 3H), 3.91 (s, 3H).

25

Example 39B

N-(3-(9-fluorenylmethoxycarbonyl)amino-4-methoxybenzoyl)-1-(3,4,5-trimethoxyphenyl)-2-aminoethanol

30 A suspension of Example 39A (765 mg, 1.96 mmol) and ethanoamine (446 mg, 1.96 mmol) in THF (20 mL) and DMF (1.5 mL) at room temperature was treated sequentially with HATU (747 mg, 1.96 mmol) and N-methylmorpholine (0.22 mL), stirred at room temperature for 18 hours, and concentrated. The concentrate was dissolved in dichloromethane, washed with water, dried (MgSO₄), filtered, and concentrated to provide 981 mg (84%) of the desired product.

35 MS (ESI(+)) m/z 621 (M+Na)⁺;

¹H NMR (CDCl₃) δ 8.46 (br s, 1H), 7.80 (d, J=9.0 Hz, 2H), 7.63 (m, 3H), 7.30-7.48 (m, 4H), 6.95 (d, J=9.0 Hz, 1H), 6.63 (s, 3H), 6.60 (m, 1H), 4.90 (m, 1H), 4.51 (d, J=9.0 Hz, 2H), 4.30 (t, J=6.0 Hz, 1H), 3.84 (s, 9H), 3.82 (s, 3H).

5

Example 39C2-(3-(9-fluorenylmethoxycarbonyl)amino-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-
Δ2,3-oxazoline

Example 39B (980 mg, 1.63 mmol) was processed as described in Example 1C to provide 920 mg of the desired product.

10

Example 39D2-(3-amino-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

A solution of Example 39C (500 mg, 0.86 mmol) in acetonitrile (5 mL) was treated with diethylamine, stirred at room temperature for 20 minutes, and concentrated.

15

The concentrate was purified by flash column chromatography on silica gel with 95:6:0.5 dichloromethane/methanol/ammonium hydroxide to provide 227 mg (74%) of the desired product.

MS (ESI(+)) m/z 359 (M+H)⁺;

¹H NMR (CDCl₃) δ 7.4 (m, 2H), 6.81 (d, J=9.0 Hz, 1H), 6.58 (s, 2H), 5.55 (m, 1H), 4.42 (m, 1H), 3.95 (m, 1H), 3.90 (s, 3H), 3.83 (s, 9H).

20

Example 402-(3-amino-4-methylphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

3-Amino-4-methylbenzoic acid (910 mg, 6.0 mmol) was processed as described in

Example 39 to provide 438 mg of the desired product.

25

MS (ESI(+)) m/z 343 (M+H)⁺;

¹H NMR (CDCl₃) δ 7.35 (m, 2H), 7.12 (d, J=9.0 Hz, 1H), 6.55 (s, 2H), 5.53 (dd, J=9.0, 12.0 Hz, 1H), 4.42 (dd, J=12.0, 15.0 Hz, 1H), 3.95 (dd, J=9.0, 15.0 Hz, 1H), 3.84 (s, 9H), 3.17 (br s, 2H).

30

Example 412-(3-(Ala-Ala-amino-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazolineExample 41A

35

A suspension of compound of Example 39 (492 mg, 1.37 mmol) and Fmoc-Ala-Ala-OH (500 mg, 1.31 mmol) in THF (35 mL) was treated sequentially with HATU (547 mg, 1.43 mmol) and N-methylmorpholine (0.16 mL, 1.45 mmol), stirred at room

temperature for 18 hours, and concentrated. The concentrate was dissolved in ethyl acetate, and the solution was washed sequentially with water, 1M NaHSO₄, saturated aqueous NaHCO₃, water, and brine, dried (MgSO₄), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 7:3 ethyl acetate/dichloromethane to provide 500 mg of the desired product.

Example 41B

2-(3-(Ala-Ala-amino-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

A solution of Example 41A (500 mg, 6.9 mmol) in acetonitrile (30 mL) was treated with diethylamine (6.0 mL), stirred for 20 minutes, and concentrated. The concentrate was purified by flash column chromatography with 93:7:1 dichloromethane/methanol/ammonium hydroxide to provide 200 mg of the desired product.

MS (ESI(+)) m/z 501 (M+H)⁺;

¹H NMR (CDCl₃) δ 8.93 (s, 1H), 8.46 (d, J=6.0 Hz, 1H), 7.76 (dd, J=3.0, 9.0 Hz, 1H), 7.15-7.25 (m, 2H), 6.91 (d, J=9.0 Hz, 1H), 6.56 (s, 2H), 5.53 (m, 1H), 4.62 (m, 1H), 4.43 (dd, J=9.0, 14.0 Hz, 1H), 3.98 (m, 1H), 3.94 (s, 3H), 3.84 (s, 6H), 3.83 (s, 3H), 3.54 (m, 1H), 2.38 (s, 1H), 1.46 (d, J=9 Hz, 3H), 1.36 (d, J=9 Hz, 3H).

Example 42

2-(3-(Ala-amino-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

Example 39 (302 mg, 0.842 mmol) and Fmoc-Ala-OH (250 mg, 0.803 mmol) were processed as described in Example 41 to provide 225 mg of the desired product.

MS (ESI(+)) m/z 430 (M+H)⁺;

¹H NMR (CDCl₃) δ 9.84 (s, 1H), 9.03 (dd, J=3.0 9Hz, 1H), 7.75 (dd, J=3.0, 9.0 Hz, 1H), 6.92 (d, J=9.0, 1H), 6.58 (d, J=3.0 Hz, 2H), 5.52 (dd, J=9.0, 12.0 Hz, 1H), 4.42 (dd, J=12, 15 Hz, 1H), 4.0 (m, 1H), 3.95 (s, 3H), 3.85 (s, 9H), 3.62 (m, 1H), 1.52 (d, J=6.0 Hz, 3H).

Example 43

2-(3-((3-aminopropionoyl)amino-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

Example 39 (302 mg, 0.842 mmol) and Fmoc-β-Ala-OH (250 mg, 0.803 mmol) were processed as described in in Examples 41 to provide 176 mg of the desired product.

MS (ESI(+)) m/z 430 (M+H)⁺;

¹H NMR (CDCl₃) δ 9.08 (s, 1H), 8.95 (s, 1H), 7.73 (dd, J=3.0, 6.0 Hz, 1H), 6.56 (s, 2H), 5.53 (m, 1H), 4.42 (m, 1H), 3.95 (m, 1H), 3.92 (s, 3H), 3.84 (s, 9H), 3.12 (t, J=3.0 Hz, 2H), 2.56 (t, J=3.0 Hz, 2H), 2.03 (br s, 2H).

Example 442-(3-(Ser-amino-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline

Example 39 (287 mg, 0.800 mmol) and Fmoc-Ser-OH (250 mg, 0.763 mmol)

5 were processed as described in in Example 41 to provide 133 mg of the desired product.
MS (ESI(+)) m/z 446 (M+H)⁺;

¹H NMR (CDCl₃) δ 9.90 (br d, 1H), 9.00 (m, 1H), 7.76 (dd, J=3.0, 9.0 Hz, 1H), 6.92 (dd, J=3.0, 9.0 Hz, 1H), 6.56 (d, J=3.0 Hz, 2H), 5.52 (m, 1H), 4.42 (m, 1H), 4.00 (m, 1H), 3.95 (s, 3H), 3.82 (s, 3H), 3.83 (s, 6H), 3.60 (m, 1H), 1.25 (br d, 1H).

10

Example 452-(3-(Gly-amino-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline

Example 39 and Fmoc-Gly-OH were processed as described in in Example 41 to provide the desired product.

15 MS (ESI(+)) m/z 416 (M+H)⁺;

¹H NMR (CDCl₃) δ 9.78 (br s, 1H), 9.02 (d, J=3.0 Hz, 1H), 7.77 (dd, J=3.0, 9.0 Hz, 1H), 6.94 (d, J=9.0 Hz, 1H), 6.58 (s, 2H), 5.56 (dd, J=9.0, 12.0 Hz, 1H), 4.43 (dd, J=12.0, 15.0 Hz, 1H), 3.98 (dd, J=9.0, 15.0 Hz, 1H), 4.97 (s, 3H), 3.86 (s, 6H), 3.85 (s, 3H), 3.51 (s, 3H).

20

Example 462-(1-Methyl-1H-pyridin-2-on-4-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazolineExample 46A1-methyl-1H-pyridin-2-one-4-carboxylic acid

25

A solution of N-methyl-4-methoxycarbonylpyridinium iodide (2.00 g, 7.16 mmol) in water (10 mL) at room temperature was treated sequentially with 14M sodium hydroxide (1.0 mL) and 1.8M K₃Fe(CN)₆ (1.5 mL), stirred for 4 hours, treated again with 1.8M K₃Fe(CN)₆ once per hour for 4 hours, heated at 55 °C for one hour, cooled to room temperature, and treated with 6M HCl to pH 3. The precipitate was collected, washed

30

with ether and dried under vacuum to provide 1.00g of the desired product.

MS (ESI(+)) m/z 154 (M+H)⁺;

¹H NMR (DMSO-d₆) δ 7.81 (d, J=7.0 Hz, 1H), 6.83 (d, J=3.0 Hz, 1H), 6.54 (dd, J=3.0, 7.0 Hz, 1H), 3.45 (s, 3H).

35

Example 46B2-(1-methyl-1H-pyridin-2-on-4-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline

Example 46A (363 mg, 2.37 mmol) was processed as described in Example 4 to provide 493 mg of the desired product.

MS (ESI(+)) m/z 345 (M+H)⁺;

¹H NMR (CDCl₃) δ 7.34 (d, J=9.0 Hz, 1H), 7.13 (d, J=3 Hz, 1H), 6.73 (dd, J=3.0, 9.0 Hz, 1H), 5.62 (dd, J=9.0, 12.0 Hz, 1H), 4.48 (dd, J=12.0, 15.0 Hz, 1H), 4.10 (dd, J=9.0, 15.0 Hz, 1H), 3.86 (s, 6H), 3.84 (s, 3H), 3.58 (s, 3H).

Example 47

2-(2-(2-hydroxyethoxy)-4-pyridinyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

10 2-(2-Hydroxyethoxy)isonicotinonitrile (350 mg, 2.6 mmol) was processed as described in Example 23F to provide 250 mg (28%) of the desired product.

MS (ESI(+)) m/z 375 (M+H)⁺;

¹H NMR (CDCl₃) δ 8.73 (d, J=3.0 Hz, 1H), 8.20 (dd, J=3.0, 9.0 Hz, 1H), 6.86 (d, J=9.0 Hz, 1H), 6.53 (s, 2H), 5.58 (dd, J=9.0, 10.0 Hz, 1H), 4.53 (m, 2H), 4.45 (dd, J=10.0, 15.0 Hz, 1H), 3.98 (m, 2H), 3.09 (t, J=6.0 Hz, 1H).

Example 48

2-(imidazo[1,2-a]pyridin-6-yl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

20

Example 48A

methyl imidazo[1,2-a]pyridin-6-carboxylate

A solution of bromoacetaldehyde diethyl acetal (3.2 mL, 21.3 mmol) in 12M HCl (0.5 mL) and water (23 mL) was heated at 90 °C for 1 hour, cooled to room temperature, treated sequentially with NaHCO₃ (1.67 g, 20 mmol) and methyl 6-aminonicotinate (1.10 g, 7.0 mmol), heated at 60 °C for 30 minutes, cooled to room temperature, adjusted to pH 9, and extracted with ethyl acetate. The extract was washed with water, dried (MgSO₄), filtered, and concentrated. The concentrate was purified by flash column chromatography with 97.5:2.5 dichloromethane/methanol to provide 1.02 g (88%) of the desired product.

MS (DCI/NH₃) m/z 177 (M+H)⁺;

30 ¹H NMR (CDCl₃) δ 8.93 (s, 1H), 7.60-7.74 (m, 4H), 3.96 (s, 3H).

Example 48B

imidazo[1,2-a]pyridin-6-carboxylic acid

35 A mixture of Example 48A (100 mg, 0.56 mmol) and 1M lithium hydroxide (0.62 mL) in THF (2 mL) was stirred at room temperature for 30 minutes, treated with 1M HCl (0.62 mL), and concentrated. The concentrate was purified by a flash column

chromatography with 85:10:5 dichloromethane/methanol/ammonium hydroxide to provide 68.4 mg (74%) of the title compound.

MS (DCI/NH₃) m/z 163 (M+H)⁺;

¹H NMR (D₂O) δ 9.15 (br s, 1H), 8.25 (d, J=12.0 Hz, 1H), 8.16 (br s, 1H), 7.92 (br s, 1H), 7.83 (d, J=12.0 Hz, 1H).

Example 48C

2-(imidazo[1,2-a]pyridin-6-yl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

Example 48B (550 mg, 0.34 mmol) was processed as described in Example 4 to provide 261 mg of the desired product.

MS (ESI(+)) m/z 354 (M+H)⁺;

¹H NMR (CDCl₃) δ 8.83 (s, 1H), 7.65-7.95 (m, 4H), 6.55 (s, 2H), 5.62 (m, 1H), 4.50 (dd, J=9.0, 15.0 Hz, 1H), 4.05 (dd, J=9.0, 15.0 Hz, 1H), 3.88 (s, 6H), 3.86 (s, 3H), 3.65 (s, 3H).

Example 49

2-(imidazo[1,5-a]pyridin-6-yl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

Example 49A

ethyl 6-hydroxymethylnicotinate

A slurry of dry calcium chloride (22.7 g, 0.205 mol) in ethanol (300 mL) and THF (300 mL) at 0 °C was treated portionwise with sodium borohydride (15.5 g, 0.41 mol), stirred for 2.5 hours, treated with dimethyl 2,5-pyridinedicarboxylate (20.0 g, 0.103 mol), stirred for 20 minutes, treated with saturated ammonium chloride solution (100 mL), and concentrated. The concentrate was dissolved in dichloromethane, and the solution was washed sequentially with saturated ammonium chloride solution, water, and brine, dried (MgSO₄), filtered, and concentrated to provide the desired product containing approximately 10% methyl 6-hydroxymethylnicotinate. This mixture was used directly in the next step without further purification.

MS (ESI(+)) m/z 182 (M+H)⁺;

¹H NMR (CDCl₃) δ 8.99 (m, 1H), 8.30 (dd, J=3.0, 9.0 Hz, 1H), 7.62 (d, J=9.0 Hz, 1H), 5.60 (t, J=3.0 Hz, 1H), 4.73 (d, J=3.0 Hz, 2H), 4.35 (q, J=7.0 Hz, 2H), 1.35 (t, J=7.0 Hz, 3H).

Example 49B

ethyl 6-formylnicotinate

A solution/slurry of Example 49 (5.00 g, 27.9 mmol) and manganese dioxide (24.3 g, 279 mmol) in dioxane (100 mL) was heated at 90 °C for 30 minutes and filtered while

hot. The filtrate was concentrated to provide 2.95 g (60%) of the desired product, which was used in the next step without further purification.

MS (DCI/NH₃) m/z 180 (M+H)⁺ and 197 (M+NH₄)⁺;

¹H NMR (DMSO-d₆) δ 10.05 (s, 1H), 9.27 (d, J=3.0 Hz, 1H), 8.50 (dd, J=3.0, 9.0 Hz, 1H), 8.05 (d, J=9.0 Hz, 1H), 4.4 (q, J=7.0 Hz, 2H), 1.45 (t, J=7.0 Hz, 3H).

Example 49C

ethyl 6-formylnicotinate oxime

A mixture of sodium acetate (8.68 g, 106 mmol), and hydroxyamine hydrochloride (7.35 g, 106 mmol) in methanol (70 mL) was stirred at room temperature for 30 minutes. The precipitate which formed was removed by filtration, and the filtrate was poured into a solution of Example 49B (6.33 g, 35.3 mmol) in methanol (20 mL), stirred at room temperature for 18 hours, and concentrated. The concentrate was dissolved in 3:1 dichloromethane/isopropanol, and this solution was washed sequentially with 1M K₂CO₃ and water, dried (MgSO₄), filtered, and concentrated to provide 6.38 g (93%) of the desired product.

Example 49D

ethyl 6-aminomethylnicotinate

A solution of Example 49C (3.40 g, 17.5 mmol) in water (40 mL) and acetic acid (53 mL) at 0 °C was treated slowly with zinc dust (5.72 g, 87.5 mmol), stirred for 20 minutes, filtered, and concentrated. The concentrate was dissolved in 3:1 dichloromethane/isopropanol, and this solution was washed sequentially with 1M Na₂CO₃ and water, dried (MgSO₄), filtered, and concentrated to provide 3.68 g (66%) of the desired product.

MS (DCI/NH₃) m/z 181 (M+H)⁺;

¹H NMR (DMSO-d₆) δ 9.04 (d, J=3.0 Hz, 1H), 8.43 (dd, J=3.0, 9.0 Hz, 1H), 7.69 (d, J=9.0 Hz, 1H), 4.36 (q, J=7.0 Hz, 2H), 1.85 (s, 2H), 1.35 (t, J=7.0 Hz, 2H), 1.02 (d, J=3.0 Hz, 1H).

Example 49E

ethyl 6-(formylamino)methylnicotinate

A solution of Example 49D (6.49 g, 36.0 mmol) in formic acid (75 mL) was refluxed for 18 hours and concentrated. The concentrate was dissolved in dichloromethane, and this solution was washed sequentially with 10% NaHCO₃ and water, dried (MgSO₄), filtered, and concentrated. The concentrate was purified by a flash

column chromatography on silica gel with 96:4 dichloromethane/methanol to provide 2.83 g (38%) of the desired product.

MS (DCI/NH₃) m/z 209 (M+H)⁺;

¹H NMR (CDCl₃) δ 9.14 (d, J=3.0 Hz, 1H), 8.35 (s, 1H), 8.28 (dd, J=3.0, 9.0 Hz, 1H),
5 7.35 (d, J=9.0 Hz, 1H), 4.67 (d, J=6.0 Hz, 2H), 4.42 (q, J=7.0 Hz, 3H), 1.41 (t, J=7.0 Hz, 3H).

Example 49F

methyl imidazo[1,5-a]pyridine-6-carboxylate

10 A solution of Example 49E (2.83 g, 13.6 mmol) in dichloromethane (30 mL) was treated with POCl₃ (2.8 mL, 30.0 mmol), stirred at 60 °C for 3 hours, and concentrated. The concentrate was treated with 1M Na₂CO₃ and extracted with dichloromethane. The extract was washed with water, dried (MgSO₄), filtered, and concentrated. The concentrate was purified by flash column chromatography with 98:2
15 dichloromethane/methanol to provide 2.64 g (93%) of the desired product.

MS (DCI/NH₃) m/z 191 (M+H)⁺;

¹H NMR (CDCl₃) δ 8.73 (s, 1H), 8.21 (s, 1H), 7.46 (s, 1H), 7.45 (d, J=9.0 Hz, 1H), 7.24 (dd, J=3.0 Hz, 9.0 Hz, 1H), 4.40 (q, J=7.0 Hz, 2H), 1.41 (t, J=7.0 Hz, 3H).

20

Example 49G

imidazo[1,5-a]pyridine-6-carboxylic acid

A solution of Example 49F (2.60 g, 13.7 mmol) in 1M LiOH (41 mL) and THF (50 mL) was stirred at room temperature for 1 hour, treated with 1M HCl (42 mL), and extracted with dichloromethane. The extract was washed with water, dried (MgSO₄),
25 filtered, and concentrated to provide 1.92 g (86%) of the desired compound, which was used in the next step without further purification.

MS (DCI/NH₃) m/z 163 (M+H)⁺;

¹H NMR (DMSO-d₆) δ 13.28 (br s, 1H), 9.08 (s, 1H), 8.65 (br s, 1H), 7.57 (d, J=9.0 Hz, 1H), 7.42 (br s, 1H), 7.12 (dd, J=2.0, 9.0 Hz, 1H).

30

Example 49H

2-(imidazo[1,5-a]pyridin-6-yl)-5-(3,4,5-trimethoxyphenyl)-Δ^{2,3}-oxazoline

Example 49G (1.92 g, 11.9 mmol) was processed as described in Example 4 to provide 337 mg (8%) of the desired product.

35 MS (ESI(+)) m/z 354 (M+H)⁺;

¹H NMR (CDCl₃) δ 8.58 (s, 1H), 8.15 (s, 1H), 7.48 (d, J=9.0 Hz, 2H), 7.31 (dd, J=3.0, 9.0 Hz, 1H), 6.56 (s, 2H), 5.58 (dd, J=9.0, 12.0 Hz, 1H), 4.46 (dd, J=12.0, 15.0 Hz, 1H), 4.02 (dd, J=9.0, 15.0 Hz, 1H), 3.85 (s, 6H), 3.83 (s, 3H).

5

Example 502-(2-methyl-6-indoliziny)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazolineExample 50AN-(2-oxo-1-propyl)-2-methyl-5-methoxycarbonylpyridinium bromide

10 A solution of methyl 6-methylnicotinate (1.00 g, 6.60 mmol) and bromoacetone (1.00g, 7.30 mmol) in acetone (3 mL) was refluxed overnight, cooled to room temperature, and decanted. The resulting solid was dried under vacuum to provide approximately 1.47 g the desired product as a solid, which was used directly in the next step without further purification.

15

Example 50Bmethyl 2-methyl-indolizine-6-carboxylate

20 A mixture of Example 50A (570 mg, 2.32 mmol) and sodium carbonate (400 mg, 5.0 mmol) in ethanol (10 mL) was refluxed for 3 hours and concentrated. The concentrate was dissolved in dichloromethane, and this solution was washed with water, dried (MgSO₄), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 2:1 hexanes/dichloromethane to provide 407 mg (93%) of the desired product.

MS (DCI/NH₃) m/z 190 (M+H)⁺;

25 ¹H NMR (DMSO-d₆) δ 8.98 (s, 1H), 7.54 (s, 1H), 7.33 (d, J=9.0 Hz, 1H), 7.11 (d, J=9.0 Hz, 1H), 6.32 (s, 1H), 3.82 (s, 3H), 2.24 (s, 3H).

Example 50C2-methyl-indolizine-6-carboxylic acid

30 A solution of Example 50A (200 mg, 1.06 mmol) in 6M HCl (20 mL) was refluxed for 3 hours and was concentrated to provide 200 mg of the desired product.

MS (DCI/NH₃) m/z 176 (M+H)⁺;

¹H NMR (DMSO-d₆) δ 8.91 (s, 1H), 7.52 (s, 1H), 7.31 (d, J=12.0 Hz, 1H), 7.10 (dd, J=3.0, 9.0 Hz, 1H), 6.31 (s, 1H), 2.25 (s, 3H).

35

Example 50D2-(2-methyl-6-indoliziny)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

Example 50C (210 mg, 0.99 mmol) was processed as described in Example 4 to provide 75.2 mg (21%) of the desired product.

MS (ESI(+)) m/z 367 (M+H)⁺;

¹H NMR (CDCl₃) δ 8.57 (br s, 1H), 7.13-7.30 (m, 3H), 6.58 (s, 2H), 6.30 (s, 1H), 5.56 (br s, 1H), 4.45 (br s, 1H), 4.00 (br s, 1H), 3.86 (s, 3H), 3.84 (s, 6H), 2.32 (s, 3H).

Example 51

2-(3-fluoro-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ^{2,3}-oxazoline

Example 51A

3-Fluoro-4-methoxybenzoic acid (1.00 g, 5.88 mmol) was processed as described in Example 4 to provide 1.37 g of the desired product.

MS (ESI(+)) m/z 380 (M+H)⁺;

¹H NMR (CDCl₃) δ 7.56-7.51 (m, 2H), 6.98 (app t, J=8.1 Hz, 1H), 6.63 (s, 2H), 6.47 (m, 1H), 4.92-4.88 (m, 1H), 3.94 (s, 3H), 3.95-3.85 (m, 1H), 3.85 (s, 6H), 3.84 (s, 3H), 3.53-3.49 (m, 1H).

Example 51B

2-(3-fluoro-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ^{2,3}-oxazoline

Example 51A (530 mg, 1.4 mmol) was processed as described in Example 4 to provide 415 mg of the desired product.

MS (ESI(+)) m/z 362 (M+H)⁺;

¹H NMR (CDCl₃) δ 7.92 (m, 1H), 7.80-7.76 (m, 1H), 7.06-7.03 (m, 1H), 6.56 (s, 2H), 5.65 (m, 1H), 4.50 (m, 1H), 4.05 (m, 1H), 3.96 (s, 3H), 3.86 (s, 3H), 3.86 (s, 6H);

Anal. calcd for C₁₉H₂₀FNO₅: C, 63.15; H, 5.58; N, 3.88. Found: C, 63.22; H, 5.68; N, 3.82.

Example 52

2-((2S)-indolin-2-yl)-5-(3,4,5-trimethoxyphenyl)-Δ^{2,3}-oxazoline

30

Example 52A

1-(tert-butoxycarbonyl)-1H-indole-2-carboxylic acid

(S)-(-)-Indoline-2-carboxylic acid (1.88 g, 11.5 mmol) was processed as described in Example 4 to provide 2.89 g of the desired product.

35 MS (ESI(+)) m/z 281 (M+NH₄)⁺;

¹H NMR (CDCl₃) δ 12.88 (br s, 1H), 8.72 (m, 1H), 7.19-7.14 (m, 2H), 6.96-6.90 (m, 1H), 4.76 (dd, J=4.1, 11.5 Hz, 1H), 3.52 (dd, J=11.5, 17.0 Hz, 1H), 3.05-2.98 (m, 1H), 2.50 (s, 9H).

5

Example 52B

tert-butyl 2-(((2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl)amino)carbonyl)-1H-indole-1-carboxylate

Example 52A (1.02 g, 3.88 mmol) was processed as described in Example 4 to provide 1.08 g of the desired product as a 1:1 mixture of diastereomers.

10 MS (ESI(+)) m/z 473 (M+H)⁺;

¹H NMR (CDCl₃) δ 7.65 (br s, 1H), 7.23-7.15 (m, 2H), 7.03-6.98 (m, 1H), 6.57 (m, 1H), 4.90-4.84 (m, 1H), 4.79-4.78 (m, 1H), 3.83 (s, 3H), 3.82 (s, 6H), 3.70-3.65 (m, 1H), 3.51-3.47 (m, 1H), 3.33-3.30 (m, 2H), 1.56 (s, 9H).

15

Example 52C

tert-butyl 2-(5-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1,3-oxazol-2-yl)-1H-indole-1-carboxylate

A solution of Example 52C (146 mg, 0.31 mmol) in chloroform (3 mL) and pyridine (0.125 mL) at 0 °C was treated with thionyl chloride (70 mL, 0.93 mmol), stirred for 20 minutes, treated with dichloromethane, washed with 10% NaHCO₃, dried (MgSO₄), filtered, and concentrated. The concentrate was purified on silica gel with 30:70 ethyl acetate/hexanes to provide 99 mg of the desired product as a mixture of diastereomers.

25

¹H NMR (CDCl₃) δ 7.61 (m, 1H), 7.22-7.14 (m, 2H), 7.02-6.97 (m, 1H), 6.57 (m, 2H), 4.95 (m, 1H), 4.91-4.86 (m, 1H), 3.97-3.86 (m, 1H), 3.84-3.82 (m, 9H), 3.60-3.42 (m, 3H), 1.55 (m, 9H);

HRMS (FAB): Calc. (M+H)⁺ for C₂₅H₃₁N₂O₆: 455.2182. Found: 455.2166.

Example 52D30

2-((2S)-indolin-2-yl)-5-(3,4,5-trimethoxyphenyl)-Δ^{2,3}-oxazoline

2-((2S)-1-Tert-butyloxycarbonylindolin-2-yl)-5-(3,4,5-trimethoxyphenyl)-Δ^{2,3}-oxazoline (86 mg, 0.19 mmol) was treated with 4M HCl in dioxane (2 mL), stirred for three hours, and concentrated. The concentrate was dissolved in dichloromethane and extracted with saturated NaHCO₃. The extract was separated, and the aqueous layer was extracted with dichloromethane. The combined extracts were dried (MgSO₄), filtered, and concentrated. The concentrate was chromatographed on silica gel with a gradient of

35

from 30 to 50% ethyl acetate/hexanes to provide 44 mg of the desired product as a mixture of diastereomers.

MS (ESI(+)) m/z 355 (M+H)⁺;

¹H NMR (CDCl₃) δ 7.53-7.43 (m, 1H), 7.11-7.06 (m, 2H), 6.86-6.80 (m, 1H), 6.74 (m, 1H), 6.60 (m, 2H), 4.95 (m, 1H), 4.47-4.39 (m, 1H), 4.01-3.86 (m, 1H), 3.85-3.81 (m, 9H), 3.68-3.52 (m, 2H), 3.10-2.97 (m, 1H).

Example 53

2-(2-chloro-4-nitrophenyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

10

Example 53A

2-chloro-N-(2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl)-4-nitrobenzamide

2-Chloro-4-nitrobenzoic acid (765 mg, 3.79 mmol) was processed as described in Example 4 to provide 735 mg of the desired product.

15 MS (ESI(+)) m/z 428 (M+NH₄)⁺;

¹H NMR (CDCl₃) δ 8.30 (d, J=2.4 Hz, 1H), 8.17 (dd, J=2.4, 8.5 Hz, 1H), 7.80 (d, J=8.5 Hz, 1H), 6.64 (s, 2H), 4.95-4.91 (m, 1H), 4.02-3.94 (m, 1H), 3.87 (s, 6H), 3.84 (s, 3H), 3.56-3.47 (m, 1H), 2.70 (d, J=3.1 Hz, 1H).

Example 53B

2-(2-chloro-4-nitrophenyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

20 Example 53A (706 mg, 1.72 mmol) was processed as described in Example 4 to provide 570 mg of the desired product.

MS (ESI(+)) m/z 393 (M+H)⁺;

25 ¹H NMR (CDCl₃) δ 8.37 (d, J=2.4 Hz, 1H), 8.18 (dd, J=2.4, 8.8 Hz, 1H), 8.05 (d, J=8.5 Hz, 1H), 6.60 (s, 2H), 5.65 (dd, J=8.5, 10.5 Hz, 1H), 4.57 (dd, J=10.2, 15.3 Hz, 1H), 4.13 (dd, J=8.5, 15.6 Hz, 1H), 3.87 (s, 6H), 3.86 (s, 3H).

Example 54

2-(2-fluoro-4-nitrophenyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

30

Example 54A

2-fluoro-N-(2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl)-4-nitrobenzamide

2-Fluoro-4-nitrobenzoic acid (702 mg, 3.79 mmol), was processed as described in Example 4 to provide 767 mg (51%) of the desired product.

MS (ESI(+)) m/z 412 (M+NH₄)⁺;

35 ¹H NMR (CDCl₃) δ 8.30 (dd, J=7.8, 8.5 Hz, 1H), 8.14 (dd, J=2.4, 8.8 Hz, 1H), 8.04 (dd, J=2.4, 11.2 Hz, 1H), 7.2-7.1 (m, 1H), 6.65 (s, 2H), 4.94-4.91 (m, 1H), 3.95 (m, 1H), 3.87 (s, 6H), 3.85 (s, 3H), 3.60-3.55 (m, 1H), 2.69 (d, J=3.1 Hz, 1H).

Example 54B2-(2-fluoro-4-nitrophenyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

Example 54A (760 mg, 1.93 mmol) was processed as described in Example 4 to provide 640 mg (88%) of the desired product.

MS (ESI(+)) m/z 377 (M+H)⁺;

¹H NMR (CDCl₃) δ 8.18-8.05 (m, 3H), 6.58 (s, 2H), 5.64 (dd, J=8.1, 9.9 Hz, 1H), 4.57 (dd, J=10.3, 15.5 Hz, 1H), 4.13 (dd, J=8.5, 15.8 Hz, 1H), 3.87 (s, 6H), 3.86 (s, 3H).

Example 552-(1,4-dimethylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

A solution of Example 6 (187 mg, 0.51 mmol) in THF (5 mL) at 0 °C was treated dropwise with 2.5 M n-butyllithium in hexane (0.22 mL, 0.56 mmol), stirred for 15 minutes, treated with methyl iodide (70 mL, 1.02 mmol), stirred for 18 hours while warming to room temperature, poured into water, and extracted with dichloromethane (2×). The combined extracts were dried (MgSO₄), filtered, and concentrated. The concentrate was purified on silica gel with a gradient of from 30% to 60% ethyl acetate/hexanes to provide 15 mg of the desired product.

¹H NMR (CDCl₃) δ 7.81 (d, J=8.5 Hz, 1H), 7.20 (d, J=8.5 Hz, 2H), 7.10 (d, J=3.3 Hz, 1H), 6.63 (d, J=2.9 Hz, 1H), 6.62 (s, 2H), 5.56 (dd, J=8.1, 10.3 Hz, 1H), 4.52 (dd, J=10.3, 14.7 Hz, 1H), 4.04 (dd, J=8.1, 14.7 Hz, 1H), 3.86 (s, 9H), 3.81 (s, 3H), 2.88 (s, 3H); HRMS (FAB) Calc.(M+H)⁺ for C₂₂H₂₅N₂O₄: 381.1830. Found, 381.1830.

Example 562-(1-methylthiothiocarbonylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

A solution of Example 11 (179 mg, 0.51 mmol) in THF (4 mL) at 0 °C was treated with sodium hydride (15 mg, 0.61 mmol), stirred for ten minutes, treated with carbon disulfide (61 mL, 1.02 mmol), stirred for 18 hours while warming to room temperature, cooled to 0 °C, treated with methyl iodide (0.1 mL, 1.53 mmol), stirred for thirty minutes at room temperature, poured into water, and extracted with ethyl acetate. The extract was dried (MgSO₄), filtered, and concentrated. The concentrate was purified on silica gel with a gradient of from 40% to 50% ethyl acetate/hexanes to provide 200 mg of the desired product.

MS (ESI(+)) m/z 443 (M+H)⁺;

¹H NMR (CDCl₃) δ 9.00 (d, J=8.8 Hz, 1H), 8.24 (d, J=1.4 Hz, 1H), 8.16 (d, J=3.7 Hz, 1H), 8.03 (dd, J=1.7, 8.8 Hz, 1H), 6.73 (dd, J=0.7, 3. Hz, 1H), 6.59 (s, 2H), 5.62 (dd,

J=8.1, 10.2 Hz, 1H), 4.49 (dd, J=9.8, 14.6 Hz, 1H), 4.03 (dd, J=8.1, 14.6 Hz, 1H), 3.85 (s, 9H), 2.82 (s, 3H);
Anal. calcd for C₂₂H₂₂N₂O₄S₂: C, 59.71; H, 5.01; N, 6.33. Found: C, 59.58; H, 5.11; N, 6.15.

5

Example 572-(1,3-dimethylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)-Δ^{2,3}-oxazolineExample 57A10 N-(2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl)-1,2-dimethyl-1H-indole-5-carboxamide

1,3-Dimethylindole-5-carboxylic acid (400 mg, 2.12 mmol) was processed as described in Example 4 to provide the desired product, which was used in the next step without further purification.

MS (ESI(+)) m/z 399 (M+H)⁺;

15

Example 57B2-(1,3-dimethylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)-Δ^{2,3}-oxazoline

Example 57A was processed as described in Example 4 to provide 490 mg of the desired product.

MS (ESI(+)) m/z 381 (M+H)⁺;

20 ¹H NMR (CDCl₃) δ 8.27 (d, J=1.5 Hz, 1H), 7.92 (dd, J=1.5, 8.5 Hz, 1H), 7.31 (d, J=8.8 Hz, 1H), 6.87 (d, J=0.7 Hz, 1H), 6.62 (s, 2H), 5.60 (dd, J=8.1, 10.3 Hz, 1H), 4.49 (dd, J=9.9, 14.3 Hz, 1H), 4.02 (dd, J=7.7, 14.3 Hz, 1H), 3.85 (s, 9H), 3.76 (s, 3H), 2.33 (d, J=0.7 Hz, 1H);

Anal. calcd for C₂₂H₂₄N₂O₄: C, 69.46; H, 6.36; N, 7.36. Found: C, 69.21; H, 6.27; N,

25 6.96.

Example 582-(6-chloroindol-5-yl)-5-(3,4,5-trimethoxyphenyl)-Δ^{2,3}-oxazoline

30

Example 58Amethyl 4-amino-2-chloro-5-iodo-benzoate

A solution of methyl 4-amino-2-chloro-benzoate (1.14 g, 6.16 mmol) in dichloromethane (30 mL) and methanol (15 mL) was treated sequentially with calcium carbonate (1.85 g, 18.5 mmol) and benzyl trimethylammonium dichloriodate (3.22 g, 9.24 mmol), stirred for 18 hours, treated with additional benzyl trimethylammonium dichloriodate (2 g, 5.75 mmol), stirred for 3 days, filtered into a separatory funnel, washed with saturated NaHSO₃, dried (MgSO₄), filtered, and concentrated. The

35

concentrate was recrystallized from ethyl acetate to provide the majority of the desired product. The filtrate was concentrated, and the concentrate was purified on silica gel with a gradient of from 10% to 20% ethyl acetate/hexanes to provide a total of 1.3 g of the desired product.

5 MS (ESI(-)) m/z 310 (M-H)⁻;

¹H NMR (CDCl₃) δ 8.25 (d, J=2.0 Hz, 1H), 6.75 (d, J=2.0 Hz, 1H), 4.52 (br s, 2H), 3.87 (s, 3H). Characterization for the minor product: ¹H NMR (300 MHz, CDCl₃) 7.72 (d, J=8.8 Hz 1H), 6.63 (d, J=8.5 Hz, 1H), 4.71 (br s, 2H), 3.88 (s, 3H).

10

Example 58B

methyl 6-chloro-5-indolecarboxylate

A 50% solution of ethyl ethynyl ether in hexanes (2.1 mL, 10.8 mmol) at 0 °C was slowly treated with 1M catechol borane in THF (9.7 mL, 9.7 mmol), warmed to room temperature, stirred for 2 hours, heated at 70 °C for 2 hours, cooled to room temperature, treated sequentially with Example 58A (1.77 g, 5.69 mmol) in THF (30 mL),
15 tetrakis(triphenylphosphine)-palladium(0) (329 mg, 0.28 mmol), and powdered sodium hydroxide (683 mg, 17.1 mmol), heated to reflux, stirred for 18 hours, cooled to room temperature, treated with 2M HCl (30 mL), stirred for 18 hours, treated with ethyl acetate, washed sequentially with water, 2M Na₂CO₃, and brine, dried (MgSO₄), filtered, and
20 concentrated. The concentrate was purified by flash column chromatography on silica gel to provide the impure desired product which was used in the next step without further purification.

25

Example 58C

6-chloro-5-indolecarboxylic acid

A solution of Example 58B (1.17 g, approximately 5.6 mmol) in THF (50 mL) was treated with 1M LiOH (56 mL, 56 mmol), heated at 50 °C, stirred for 18 hours, treated with 1M NaOH, washed with diethyl ether, acidified with HCl, and extracted with ethyl acetate. The extract was dried (MgSO₄), filtered, and concentrated. The concentrate
30 was purified on silica gel with 50% ethyl acetate/hexanes to provide of 660 mg of the desired product.
¹H NMR (DMSO-d₆) δ 12.73 (br s, 1H), 11.45 (s, 1H), 8.13 (s, 1H), 7.49 (m, 2H), 6.57 (m, 1H).

35

Example 58D

6-chloro-N-(2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl)-1H-indole-5-carboxamide

Example 58C (660 mg, 3.38 mmol) was processed as described in Example 4A to provide 128 mg of the desired product.

MS (ESI(+)) m/z 405 (M+H)⁺;

¹H NMR (CDCl₃) δ 8.29 (br s, 1H), 8.00 (s, 1H), 7.44 (s, 1H), 7.28 (m, 1H), 6.68 (s, 2H),
5 6.66 (m, 1H), 6.59 (m, 1H), 4.99 (m, 1H), 4.00-3.92 (m, 1H), 3.88 (s, 6H), 3.85 (s, 3H),
3.63-3.55 (m, 1H), 3.45 (d, J=3.7 Hz, 1H).

Example 58E

2-(6-chloroindol-5-yl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

10 Example 58D (63 mg, 0.156 mmol) was processed as described in Example 4B to provide 36 mg of the desired product.

¹H NMR (CDCl₃) δ 9.09 (br s, 1H), 8.11 (s, 1H), 7.38 (s, 1H), 7.16 (m, 1H), 6.59 (s, 2H),
6.45 (m, 1H), 5.66 (dd, J=8.1, 9.8 Hz, 1H), 4.51 (dd, J=10.5, 14.2 Hz, 1H), 4.07 (dd,
J=8.5, 14.6 Hz, 1H), 3.80 (s, 6H), 3.79 (s, 3H);

15 HRMS (FAB) Calc. (M+H)⁺ for C₂₀H₂₀ClN₂O₄: 387.1112. Found: 387.1110.

Example 59

2-(1-methyloxindol-5-yl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

20

Example 59A

benzyl 1-methyl-oxindole-5-carboxylate

A solution of 5-bromo-1-methyl oxindole (3.75 g, 16.6 mmol) and triethylamine (3.48 mL) in THF (40 mL) was treated with benzyl alcohol (2.58 mL) and PdCl₂(dppf) (300 mg), stirred under carbon monoxide (680 psi) at 130 °C for 16 hours, depressurized,
25 filtered through diatomaceous earth (Celite®), and concentrated. The concentrate was
purified on silica gel with 30% ethyl acetate/hexanes to provide 2.36 g of the desired
product.

MS (ESI(+)) m/z 299 (M+NH₄)⁺;

¹H NMR (CDCl₃) δ 8.10-8.07 (m, 1H), 7.95 (s, 1H), 7.47-7.33 (m, 5H), 6.86 (d, J=8.1
30 Hz, 2H), 5.35 (s, 2H), 3.56 (s, 2H), 3.25 (s, 3H).

Example 59B

1-methyl-oxindole-5-carboxylic acid

A solution of Example 59A (1.2 g, 4.27 mmol) in ethyl acetate (30 mL) and
35 methanol (20 mL) was treated with 10% Pd/C (200 mg), stirred under hydrogen (balloon)
for 18 hours, filtered through diatomaceous earth (Celite®) with 9:1

dichloromethane/methanol solution rinses, and concentrated to provide 460 mg of the desired product.

^1H NMR (DMSO- d_6) δ 7.92 (dd, $J=1.1, 8.1$ Hz, 1H), 7.80 (d, $J=0.7$ Hz, 1H), 7.07 (d, $J=8.1$ Hz, 1H), 3.62 (s, 2H), 3.15 (s, 3H).

5

Example 59C

N-(2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl)-1-methyl-2-oxo-5-indolinecarboxamide

Example 59B (430 mg, 2.25 mmol) was processed as described in Example 4A to provide 340 mg of the desired product.

10 MS (ESI(+)) m/z 401 ($M+H$) $^+$;

^1H NMR (DMSO- d_6) δ 8.38 (app t, $J=5.5$ Hz, 1H), 7.83 (d, $J=8$ Hz, 1H), 7.77 (s, 1H), 7.05 (d, $J=8.1$ Hz, 1H), 6.65 (s, 2H), 5.52 (d, $J=4.4$ Hz, 1H), 4.74-4.68 (m, 1H), 3.74 (s, 6H), 3.63 (s, 3H), 3.61 (s, 2H), 3.48-3.37 (m, 1H), 3.15 (s, 3H).

15

Example 59D

2-(1-methyloxindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline

Example 59C (110 mg, 0.275 mmol) was processed as described in Example 4B to provide 50 mg of the desired product.

20 ^1H NMR (CDCl_3) δ 8.00 (m, 1H), 7.91 (s, 1H), 6.87 (d, $J=8.0$ Hz, 1H), 6.57 (s, 2H), 5.57 (dd, $J=8.1, 9.7$ Hz, 1H), 4.45 (dd, $J=10.2, 14.8$ Hz, 1H), 4.00 (dd, $J=8.5, 14.8$ Hz, 1H), 3.85 (s, 9H), 3.56 (s, 2H), 3.25 (s, 3H);

HRMS (FAB) Calc. ($M+H$) $^+$ for $\text{C}_{21}\text{H}_{23}\text{N}_2\text{O}_5$: 383.1607; Found: 383.1607.

Anal. calcd for $\text{C}_{21}\text{H}_{23}\text{N}_2\text{O}_5$: C, 65.96; H, 5.80; N, 7.33. Found: C, 65.71; H, 5.85; N,

25 7.15.

Example 60

2-(6-Chloro-1-methylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline

A solution of Example 58 (70 mg, 0.18 mmol) in THF (5 mL) at 0 °C was treated
30 with sodium hydride (9 mg, 0.36 mmol), stirred for ten minutes, treated with methyl iodide (34 mL, 0.54 mmol), stirred for 1 hour at 0 °C and for 1.5 hours at room temperature, treated with additional sodium hydride (9 mg, 0.36 mmol) and methyl iodide (0.1 mL), stirred for 18 hours at room temperature, poured into water, and extracted with ethyl acetate. The extract was dried (MgSO_4), filtered, and concentrated. The concentrate
35 was purified on silica gel with 1:1 ethyl acetate/hexanes to provide 55 mg of the desired product.

¹H NMR (CDCl₃) δ 8.15 (s, 1H), 7.43 (s, 1H), 7.10 (d, J=3.1 Hz, 1H), 6.66 (s, 2H), 6.51 (dd, J=0.7, 3.1 Hz, 1H), 5.60 (dd, J=8.1, 9.8 Hz, 1H), 4.55 (dd, J=10.2, 14.9 Hz, 1H), 4.08 (dd, J=8.1, 14.6 Hz, 1H), 3.87 (s, 6H), 3.85 (s, 3H), 3.79 (s, 3H);

HRMS (FAB) Calc. (M+H)⁺ for C₂₁H₂₂ClN₂O₄: 401.1268; Found: 401.1256;

5 Anal. calcd for C₂₁H₂₁ClN₂O₄ 0.5 H₂O: C, 61.54; H, 5.41; N, 6.83. Found: C, 61.29; H, 5.47; N, 6.72.

Example 61

2-(1-difluoromethylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)-Δ^{2,3}-oxazoline

10 A solution of Example 11 (427 mg, 1.21 mmol) in THF (5 mL) at 0 °C was treated with sodium hydride (35 mg, 1.46 mmol), stirred for 15 minutes, cooled to -78 °C, treated with excess difluorochloromethane, stirred for 18 hours warming slowly to room temperature, poured into 5.5M NH₄Cl and extracted with ethyl acetate. The extract was dried (MgSO₄), filtered, and concentrated. The concentrate was purified on silica gel with
15 s gradient of from 50% to 60% ethyl acetate/hexanes to provide 16.9 mg of the desired product.

¹H NMR (CDCl₃) δ 8.37 (s, 1H), 8.03 (m, 1H), 7.56 (d, J=8.5 Hz, 1H), 7.29 (d, J=3.7 Hz, 1H), 7.22 (t, J=60.7 Hz, 1H), 6.66 (d, J=3.4 Hz, 1H), 6.53 (s, 2H), 5.65 (dd, J=8.8, 9.5 Hz, 1H), 4.47 (dd, J=10.2, 14.2 Hz, 1H), 4.03 (dd, J=8.5, 14.2 Hz, 1H), 3.78 (s, 9H).

20

Example 62

2-(3-chloro-1-methylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)-Δ^{2,3}-oxazoline

Example 62A

methyl 3-chloro-5-indolecarboxylate

25

A solution of methyl 5-indolecarboxylate (501.1 mg, 2.65 mmol) in methanol (15 mL) was treated with N-chlorosuccinimide (425.4 mg, 3.18 mmol), stirred for 18 hours, and concentrated. The concentrate was dissolved into ethyl acetate, and this solution was washed with 1M NaHCO₃ (2×), dried (MgSO₄), filtered, and concentrated. The
30 concentrate was purified on silica gel with 15% ethyl acetate/hexanes to provide 368.8 mg of the desired product.

MS (ESI(+)) m/z 224 (M+H)⁺;

¹H NMR (CDCl₃) δ 8.39 (s, 1H), 7.97 (dd, J=1.4, 10.2 Hz, 1H), 7.32 (dd, J=0.7, 9.5 Hz, 1H), 7.1 (s, 1H), 3.95 (s, 3H), 3.79 (s, 3H).

35

Example 62B

3-chloro-5-indolecarboxylic acid

A solution of Example 62A (361 mg, 1.62 mmol) in THF (7 mL) and 1M LiOH (3.3 mL) was heated at 50 °C for 5 hours, treated with ethyl acetate and extracted with 10% NaHCO₃ (3×). The extract was treated with 6M HCl and extracted with ethyl acetate (2×40 mL). The organic layer was dried (MgSO₄), filtered, and concentrated to provide 253.2 mg of the desired compound.
MS (ESI(+)) m/z 211 (M+H)⁺;
¹H NMR (CDCl₃) δ 12.71 (s, 1H), 8.14 (s, 1H), 7.84 (dd, J=2.2, 8.8 Hz, 1H), 7.69 (s, 1H) 7.6 (dd, J=2.2, 11.0 Hz, 1H), 3.83 (s, 3H), 3.35 (s, 3H).

10

Example 62C3-chloro-N-(2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl)-1-methyl-1H-indole-5-carboxamide

3-Chloro-5-indolecarboxylic acid (182.3 mg, 0.870 mmol) was processed as described in Example 4A to provide 226.7 mg of the desired product.

15

MS (ESI(+)) m/z 419 (M+H)⁺;
¹H NMR (CDCl₃) δ 8.01 (d, J=1.35 Hz, 1H), 7.76 (dd, J=1.7, 10.5 Hz, 1H), 7.31(d, J=8.5 Hz, 1H), 7.11 (s, 1H), 6.66 (s, 2H), 4.97-4.94 (m, 1H), 3.89 (s, 3H), 3.84 (s, 3H), 3.80 (s, 3H).

20

Example 62D2-(3-chloro-1-methylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)-Δ^{2,3}-oxazoline

Example 62B (199.4 mg, 0.476 mmol) was processed as described in Example 4B to provide 78.4 mg of the desired product.

25

MS (ESI(+)) m/z 401 (M+H)⁺;
¹H NMR (CDCl₃) δ 8.31 (d, J=1.5 Hz, 1H), 7.97 (dd, J=1.47 Hz, 10.3, 1H), 7.36 (d, J=8.8 Hz, 1H), 6.61 (s, 2H), 5.64-5.58 (m, 1H), 4.53-4.45 (m, 1H), 3.85 (s, 6H), 3.81(s, 3H);
Anal. calcd for C₂₁H₂₁N₂O₄Cl: C, 62.92; H, 5.28; N, 6.99. Found: C, 62.63; H, 5.17; N, 6.70.

30

Example 632-(7-fluoro-5-indolyl)-5-(3,4,5-trimethoxyphenyl)-Δ^{2,3}-oxazolineExample 63A

35

3-fluoro-4-nitrophenyl triflate

To a mixture of 3-fluoro-4-nitrophenol (0.628 g, 4 mmol) and triethyl amine (1.62 g, 16 mmol) in 50 ml of anhydrous Dichloromethane was added trifluoromethanesulfonyl

anhydride (2.27 g, 8 mmol) by syringe at 0°C. The solution was stirred at that temperature for another 4 hours or until the TLC indicated all starting material was consumed. The solution was poured in 100 ml of water, washed by 5% NaHCO₃, brine and , dried (MgSO₄), filtered, and concentrated. After filtration, the organic solution was concentrated *in vacuo*. The crude material was purified by flash chromatography on silica gel eluting with 2:8 Ethyl acetate/Hexanes to provide 1.10 g of the desired product (98%).
¹H NMR (CDCl₃) δ 8.25 (m, 1H), 7.30 (m, 2H).

Example 63B

7-fluoro-5-indole-triflate

A solution of solution of Example 63A (1.10 g, 3.8 mmol) in THF (50 mL) at -40 °C was treated over 5 minutes with 1M vinylmagnesium bromide in THF (11.4 ml, 11.4 mmol), stirred for 1 hour, poured into saturated NH₄Cl, and extracted with ethyl acetate. The extract was washed with brine, dried (MgSO₄), filtered, and concentrated. The concentrate was purified by flash chromatography on silica gel with 15:85 ethyl acetate/hexanes to provide 0.315 g of the desired product.
MS (DCI/NH₃) m/z 283 (M+NH₄-H₂O)⁺;
¹H NMR (CDCl₃) δ 8.65 (br s, 1H), 7.36 (m, 2H), 6.92 (dd, J=10.5, 2.3 Hz, 1H), 6.65 (m, 1H).

Example 63C

methyl-7-fluoro-5-indole-carboxylate

A mixture of Example 63B (1.188 g, 4.2 mmol), PdCl₂(dppf)₂, and triethylamine (1.08 mL, 8.4 mmol) in methanol (40 mL) at 120 °C under carbon monoxide (450 psi) was stirred, for 15 hours, cooled to room temperature, filtered through diatomaceous earth (Celite®), and concentrated. The concentrate was purified by flash chromatography on silica gel with 15:85 ethyl acetate/hexanes to provide 0.63 g of the desired product.
MS (DCI/NH₃) m/z 194 (M+H)⁺ and 211(M+NH₄)⁺;
¹H NMR (CDCl₃) δ 8.65 (br s, 1H), 7.62 (dd, J=1.1, 11.7 Hz, 2H), 6.31 (m, 1H), 6.97 (dd, J=3.3, 5.5 Hz, 1H), 3.94 (s, 3H).

Example 63D

7-fluoro-1H-indole-5-carboxylic acid

A mixture of Example 63C (0.22 g, 1.13 mmol) and LiOH (0.136g, 5.7 mmol) in 1:1 methanol/water (20 ml) was heated at reflux for 2 hours, poured into water (1 mL), and extracted with ethyl acetate. The extract was washed with brine, dried (MgSO₄),

filtered, and concentrated to provide the desired product which was used in the next step without further purification.

Example 63E

5 7-fluoro-indole-5-carboxylic acid (N-[2-hydroxy-2-(3,4,5-trimethoxyphenyl) ethyl])
amide

A solution of Example 63D in DMF (10 mL) was treated sequentially with 2-amino-1-(3,4,5-trimethoxyphenyl)ethanol hydrochloric acid salt (0.343 g, 1.30 mmol), EDC (0.325 g, 1.7 mmol), triethylamine, DMAP (catalytic), heated at 50°C for 15 hours, cooled to room temperature, poured into water (100 ml), and extracted with ethyl acetate. The extract was washed with brine, dried (MgSO₄), filtered, and concentrated. The concentrate was purified by flash chromatography on silica gel with 8:2 ethyl acetate/hexanes to provide 0.24g of the desired product.

MS (DCI/NH₃) m/z 371 (M+H)⁺ and 389 (M+NH₄)⁺;
¹H NMR (CDCl₃) δ 8.51 (br s, 1H), 7.75 (s, 1H), 7.41 (d, J=11.2 Hz, 1H), 7.32 (m, 1H), 6.65 (s, 2H), 6.55 (m, 1H), 4.95 (m, 1H), 3.6-4.0 (m, 11H).

Example 63F

2-(7-fluoro-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline

A mixture of Example 63E (0.24g, 0.62 mmol) and Burgess's agent (0.176g, 0.74 mmol) in of anhydrous THF (10 mL) was heated at reflux for 1 hour, cooled to room temperature, poured into water (50 mL), and extracted with ethyl acetate. The extract was washed with brine, and , dried (MgSO_4), filtered, and concentrated. The solution was concentrated under vacuum. The concentrate was purified by flash column chromatography on silica gel to provide 0.15 g of the desired product.

MS (ESI(+)) m/z 371 ($\text{M}+\text{H}$)⁺;

¹H NMR ($\text{DMSO}-d_6$) δ 11.96 (s, 1H), 8.00 (s, 1H), 7.52 (s, 1H), 7.48 (dd, $J=0.7, 12.1$ Hz, 1H), 6.69 (s, 2H), 6.66 (s, 1H), 5.70 (m, 1H), 4.38 (m, 1H), 3.78 (m, 1H), 3.76 (s, 6H), 3.65 (s, 3H);

Anal. calcd for $\text{C}_{20}\text{H}_{19}\text{N}_2\text{O}_4\text{F}$: C, 64.86; H, 5.17; N, 7.56. Found: C, 65.05; H, 5.20; N, 7.43.

Example 64

2-(1-methyl-7-fluoro-5-indolyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

35 Example 63 (0.100 g, 0.27 mmol) in DMF (3 mL) was treated with 60% NaH (92 mg, 2.31 mmol) at 0°C, stirred for 15 minutes, treated with methyl iodide (76 mg, 0.54 mmol) in DMF (1 mL), stirred for 1 hour, treated with water, and extracted with ethyl

acetate. The extract was dried (MgSO_4), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel to provide 101 mg of the desired product.

MS (ESI(+)) m/z 385 ($\text{M}+\text{H}$)⁺;

5 ¹H NMR ($\text{DMSO}-d_6$) δ 7.98 (s, 1H), 7.45 (m, 2H), 6.68 (s, 2H), 6.61 (m, 1H), 5.68 (m, 1H), 4.20 (m, 1H), 3.98 (s, 3H), 3.90 (m, 1H), 3.74 (s, 6H), 3.65 (s, 3H);
Anal. calcd for $\text{C}_{21}\text{H}_{21}\text{N}_2\text{O}_4\text{F}$: C, 65.61; H, 5.51; N, 7.29. Found: C, 65.55; H, 5.62; N, 7.24.

10

Example 65

2-(7-chloro-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline

Example 65A

1-acetyl-5-bromo-7-chloro-indoline

15 A mixture of 1-acetyl-5-bromo-indoline (1.20 g, 5 mmol) and N-chlorosuccinimide (0.734 g, 5.5 mmol) in acetonitrile (80 mL) was heated to reflux for 12 hours, cooled to room temperature, and concentrated. The concentrate was purified by flash column chromatography on silica gel to provide 0.548 g of the desired product.

MS (ESI(+)) m/z 275 ($\text{M}+\text{H}$)⁺ and 292 ($\text{M}+\text{NH}_4$)⁺;

20 ¹H NMR (CDCl_3) δ 7.38 (m, 1H), 7.27 (m, 1H), 4.17 (t, $J=7.7$ Hz, 2H), 3.04 (t, $J=7.7$ Hz, 2H), 2.28 (s, 3H).

Example 65B

5-bromo-7-chloro-indoline

25 Example 65A was hydrolyzed with excess LiOH in methanol/water to provide the desired product.

MS (ESI(+)) m/z 233 ($\text{M}+\text{H}$)⁺ and 250 ($\text{M}+\text{NH}_4$)⁺;

¹H NMR (CDCl_3) δ 7.13 (d, $J=1.7$ Hz, 1H), 7.07 (d, $J=1.3$ Hz, 1H), 3.97 (s, 1H), 3.62 (t, $J=8.5$ Hz, 2H), 3.09 (t, $J=8.5$ Hz, 2H).

30

Example 65C

5-bromo-7-chloro-indole

A mixture of Example 65B (0.120 g, 0.55 mmol) and salcomine (0.022 g, 0.06 mmol) in methanol (30 mL) was treated with oxygen over 18 hours and concentrated.

35 The concentrate was purified by flash column chromatography on silica gel to provide 0.112 g of the desired product.

MS (ESI(+)) m/z 232 ($\text{M}+2$) and 248 ($\text{M}+\text{NH}_4$)⁺;

¹H NMR (CDCl₃) δ 8.38 (s, 1H), 7.67 (dd, J=1.7, 0.6 Hz, 1H), 7.33 (d, J=1.7 Hz, 1H), 7.26 (m, 1H), 6.53 (dd, J=2.0, 3.1 Hz, 1H).

Example 65D

5 methyl-7-chloro-5-indole-carboxylate

5-Bromo-7-chloro-indole was processed as described in Example 63C to provide the desired product.

MS (ESI(+)) m/z 210 (M+H)⁺ and 227 (M+NH₄)⁺;

¹H NMR (CDCl₃) δ 8.58 (s, 1H), 8.33 (s, 1H), 7.92 (d, J=1.1 Hz, 1H), 7.33 (m, 1H), 6.70
10 (dd, J=2.2, 2.9 Hz, 1H), 3.94(s, 3H).

Example 65E

2-(7-chloro-5-indolyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

Example 65D was processed as described in Examples 63D and 63E to provide the
15 desired product.

MS (ESI(+)) m/z 387 (M+H)⁺;

¹H NMR (DMSO-d₆) δ 11.85 (s, 1H), 8.13 (d, J=1.1 Hz, 1H), 7.72 (d, J=1.1 Hz, 1H), 7.52
(d, J=2.9 Hz, 1H), 6.69 (m, 3H), 5.70 (m, 1H), 4.78 (m, 1H), 3.78 (m, 1H), 3.76 (s,
6H), 3.65 (s, 3H);

20 Anal. calcd for C₂₀H₁₉N₂O₄Cl·0.22CH₃C(O)OCH₂CH₃: C, 61.74; H, 5.15; N, 6.90.
Found: C, 61.51; H, 4.97; N, 7.06.

Example 66

2-(1-methyl-7-chloro-5-indolyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

25 Example 65 was processed as described in Example 60 to provide the desired product.

MS (ESI(+)) m/z 401 (M+H)⁺;

¹H NMR (DMSO-d₆) δ 8.10 (d, J=1.3 Hz, 1H), 7.68 (d, J=1.2 Hz, 1H), 7.52 (s, J=3 Hz,
1H), 6.68 (s, 2H), 6.63 (d, J=2.9 Hz, 1H), 5.65 (m, 1H), 4.37 (m, 1H), 4.13 (s, 3H), 3.88
30 (m, 1H), 3.76 (s, 6H), 3.66 (s, 3H);

Anal. calcd for C₂₁H₂₁N₂O₄Cl: C, 62.92; H, 5.28; N, 6.99. Found: C, 62.72; H, 5.43; N, 6.73.

Example 67

35 2-(3-fluoro-5-indolyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

Example 67A

methyl-3-fluoro-5-indole-carboxylate

A solution of methyl 5-indole carboxylate (1.75 g, 10 mmol) and N-fluoro-2,4,6-trimethylpyridinium triflate (3.75 g, 13 mmol) in methanol (100 mL) was heated at reflux for 18 hours and concentrated. The concentrate was purified by flash column chromatography on silica gel to provide 200 mg of the desired product.

MS (ESI(+)) m/z 194 (M+H)⁺ and 211 (M+NH₄)⁺;

¹H NMR (CDCl₃) δ 8.42 (s, 1H), 7.92 (dd, J=1.7, 8.9 Hz, 1H), 7.92 (d, J=1.1 Hz, 1H), 7.80 (s, 1H), 7.34 (dd, J=2.4, 8.9 Hz, 1H), 7.04 (d, J=2.8 Hz, 1H), 3.94 (s, 3H).

Example 67B3-fluoro-indole-5-carboxylic acid (N-(2-hydroxy-2-(3,4,5-trimethoxyphenyl) ethyl)) amide

Methyl-3-fluoro-5-indole-carboxylate was processed as described in Example 63D to provide the desired product.

MS (ESI(+)) m/z 389 (M+H)⁺ and 406 (M+NH₄)⁺;

¹H NMR (CDCl₃) δ 8.08 (s, 1H), 7.90 (s, 1H), 7.67 (dd, J=1.9, 8.8 Hz, 1H), 7.32 (dd, J=2.2, 8.5 Hz, 1H), 7.05 (m, 1H), 6.51 (s, 2H), 6.66 (s, 2H), 6.63 (m, 1H), 4.95 (m, 1H), 3.91 (m, 1H), 3.85 (s, 9H), 3.70 (m, 1H), 3.60 (m, 1H).

Example 67C2-(3-fluoro-5-indolyl)-5-(3,4,5-trimethoxyphenyl)-Δ^{2,3}-oxazoline

Example 67B was processed as described in Example 63E to provide the desired product.

MS (ESI(+)) m/z 370 (M+H)⁺;

¹H NMR (DMSO-d₆) δ 11.18 (m, 1H), 8.07 (d, J=1.0 Hz, 1H), 7.78 (m, 1H), 7.47-7.52 (m, 1H), 6.69 (s, 2H), 5.68 (m, 1H), 4.38 (m, 1H), 3.86 (m, 1H), 3.76 (s, 6H), 3.66 (s, 3H);

HRMS: Calcd. (M+H)⁺: 371.1407. Found: 371.1414.

Example 68(2-(1-methyl-3-fluoro-5-indolyl)-5-(3,4,5-trimethoxyphenyl)-Δ^{2,3}-oxazoline

Example 67 was processed as described in Example 60 to provide the desired product.

MS (ESI(+)) m/z 370 (M+H)⁺;

¹H NMR (DMSO-d₆) δ 8.08 (s, 1H), 7.83 (d, J=8.5 Hz, 1H), 7.58 (d, J=8.8 Hz, 1H), 6.69 (s, 2H), 5.69 (m, 1H), 4.38 (m, 1H), 3.86 (m, 1H), 3.75-3.77 (m, 9H), 3.65 (s, 3H);

Anal. calcd for $C_{21}H_{21}N_2O_4F$: C, 65.61; H, 5.51; N, 7.29. Found: C, 65.56; H, 5.78; N, 7.00.

Example 69

5 2-(1-hydroxymethylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline

A mixture of Example 11 (0.716 g, 0.500 mmol) in ethanol (3 mL) was treated sequentially with 37% aqueous formaldehyde (2.5 mL) and 1M NaOH (10 drops), stirred for 3.5 hours to form a thick, white precipitate, treated with water (60 mL) and brine (20 mL), and extracted sequentially with 1:1 dichloromethane/ethyl acetate (80 mL) and
10 dichloromethane (20 mL). The combined extracts were washed with brine (25 mL), dried ($MgSO_4$), filtered, and concentrated to provide 146 mg of the desired product.

1H NMR ($DMSO-d_6$) δ 3.65 (s, 3H), 3.75 (s, 6H), 3.87 (dd, $J=7.9, 14.5$ Hz, 1H), 4.38 (dd, $J=9.7, 14.5$ Hz, 1H), 5.55 (d, $J=7.2$ Hz, 2H), 5.68 (dd, $J=7.9, 9.7$ Hz, 1H), 6.53 (t, $J=7.2$ Hz, 1H), 6.57 (d, $J=3.0$ Hz, 1H), 6.69 (s, 2H), 7.50 (d, $J=3.0$ Hz, 1H), 7.64 (d, $J=8.6$ Hz,
15 1H), 7.79 (dd, $J=1.0, 8.6$ Hz, 1H), 8.16 (d, $J=1.0$ Hz, 1H);

HRMS (FAB) Calc. $(M+H)^+$ for $C_{21}H_{23}N_2O_5$: 383.1607. Found: 383.1611.

Anal. calcd for $C_{21}H_{22}N_2O_5 \cdot 0.30 H_2O$: C, 65.04; H, 5.87; N, 7.22. Found: C, 65.06; H, 5.88; N, 7.20.

20 Example 70

2-(1-methoxymethyl-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline

A slurry of NaH (0.120 g, 3.00 mmol) in DMF (1.5 mL) at 0 °C was treated in one portion with Example 11 (0.106 g, 0.300 mmol), stirred for 5 minutes, treated with methoxymethyl chloride (29.0 mg, 0.360 mmol), warmed to room temperature over 20
25 hours, cooled to 0 °C, carefully quenched with methanol, added to water (20 mL), treated with 10% $NaHCO_3$ (10 mL) and brine (10 mL), and extracted with ethyl acetate (20 mL then 3×10 mL). The combined extracts were, dried ($MgSO_4$), filtered through a short plug of silica gel with ethyl acetate rinses, and concentrated. The concentrate was purified by radial chromatography with 98:2 dichloromethane/ methanol to provid the 82.4 mg of the
30 desired product.

1H NMR ($CDCl_3$) δ 3.26 (s, 3H), 3.85 (app s, 9H), 4.01 (dd, $J=8.2, 14.6$ Hz, 1H), 4.48 (dd, $J=10.0, 14.6$ Hz, 1H), 5.48 (s, 2H), 5.60 (dd, $J=8.2, 10.0$ Hz, 1H), 6.60 (s, 2H), 6.60-6.61 (m, 1H), 7.23 (d, $J=3.4$ Hz, 1H), 7.53 (d, $J=8.6$ Hz, 1H), 7.96 (dd, $J=1.4, 8.6$ Hz, 1H), 8.32 (d, $J=1.4$ Hz, 1H);

35 HRMS (FAB) Calc. $(M+H)^+$ for $C_{22}H_{25}N_2O_5$: 397.1763. Found: 397.1752.

Anal. calcd for $C_{22}H_{24}N_2O_5 \cdot 1.6 H_2O$: C, 66.65; H, 6.10; N, 7.07. Found: C, 62.12; H, 5.61; N, 6.25.

Example 712-(1,2-dimethyl-5-indolyl)-4,5-trimethoxyphenyl)- Δ 2,3-oxazoline

5

Example 71Aethyl 2-methyl-3-thiomethoxy-5-indolecarboxylate

A solution of ethyl 4-aminobenzoate (2.53 g, 15.0 mmol) in dichloromethane (75 mL)

at -70 °C was treated dropwise with trimethylacetyl chloride (1.62 g, 14.9 mmol) in dichloromethane (7.5 mL), stirred for 1 hour, treated dropwise with a solution of (methylthio)acetone (1.59 g, 15.0 mmol) in dichloromethane (7.5 mL), stirred for 1.25 hours, treated with triethylamine (1.52 g, 15.0 mmol), stirred for 10 minutes, warmed to room temperature, stirred for 16 hours, washed with water (15 mL), dried (MgSO₄), filtered, and concentrated. The concentrate was purified by flash column chromatography with 1:4 hexane/dichloromethane to provide the desired product.

MS (ESI(+)) m/z 50 (M+H)⁺;

¹H NMR (DMSO-d₆) δ 1.43 (t, J=7.0 Hz, 3H), 2.20 (s, 3H), 2.48 (s, 3H), 4.32 (q, J=7.0 Hz, 2H), 7.39 (d, J=8.5 Hz, 1H), 7.72 (dd, J=1.7, 8.5 Hz, 1H), 8.17 (d, J=1.7 Hz, 1H), 11.68-11.72 (br, 1H).

20

Example 71Bethyl 2-methyl-5-indolecarboxylate

A solution of ethyl 2-methyl-3-thiomethoxy-5-indolecarboxylate (1.90 g, 7.62 mmol) in ethanol (60 mL) at room temperature was treated with Raney Ni (approximately 3 teaspoons), stirred for 17 hours, filtered, and concentrated to provide 1.51 g of the desired product.

MS (ESI(+)) m/z 204 (M+H)⁺;

¹H NMR (DMSO-d₆) δ 1.32 (t, J=7.0 Hz, 3H), 2.40 (s, 3H), 4.28 (q, J=7.0 Hz, 2H), 6.27 (s, 1H), 7.33 (d, J=2.4 Hz, 1H), 7.64 (dd, J=1.8, 8.4 Hz, 1H), 7.10 (d, J=1.8 Hz, 1H), 11.32 (s, 1H).

30

Example 71Cethyl 1,2-dimethyl-5-indolecarboxylate

A 60% oil dispersion of NaH (1.51 g, 7.43 mmol) was rinsed with THF (2 \times 10 mL), slurried in DMF (35 mL), and cooled to 0 °C. This slurry was treated dropwise with ethyl 1,2-dimethyl-5-indolecarboxylate (1.51 g, 7.43 mmol) in DMF (5 mL), stirred for 5 minutes, treated with methyl iodide (1.11 g, 7.80 mmol), warmed to room temperature,

35

stirred for 4 hours, treated with ethyl acetate (25 mL), cooled to 0 °C, treated with ethanol (approximately 5 mL), treated with ethyl acetate (125 mL), washed sequentially with 2:1:1 water/saturated Na₂CO₃/brine (100 mL then 2×50 mL) and brine (50 mL), dried (MgSO₄), filtered, through silica gel with ethyl acetate rinses, and concentrated to provide 1.61 g of the desired product.

MS (ESI(+)) m/z 218 (M+H)⁺.

Example 71D

2-(1,2-dimethyl-5-indolyl)-4,5-trimethoxyphenyl)-Δ2,3-oxazoline

Ethyl 1,2-dimethyl-5-indolecarboxylate was processed as described in Examples 63D and 63E to provide 155 mg of the desired product.

MS (ESI(+)) m/z 381 (M+1);

¹H NMR (DMSO-d₆) δ 2.42 (s, 3H), 3.65 (s, 3H), 3.70 (s, 3H), 3.75 (s, 6H), 3.85 (dd, J=8.0, 14.5 Hz, 1H), 4.36 (dd, J=9.9, 14.5 Hz, 1H), 5.65 (dd, J=8.0, 9.9 Hz, 1H), 6.33 (s, 1H), 6.68 (s, 2H), 7.46 (d, J=8.7 Hz, 1H), 7.69 (dd, J=1.4, 8.7 Hz, 1H), 8.03 (d, J=1.4 Hz, 1H);

Anal. calcd for C₂₂H₂₄N₂O₄ 0.55 H₂O: C, 67.69; H, 6.48; N, 7.18. Found: C, 67.75; H, 6.45; N, 7.13.

20

Example 72

2-(7-methyl-5-indolyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

Example 72A

3-methyl-4-nitrophenyl trifluoromethanesulfonate

A solution of 3-methyl-4-nitrophenol, Example 72A, (5.00 g, 32.6 mmol) and triethylamine (9.90 g, 97.8 mmol) in dichloromethane (100 mL) at 0 °C was treated dropwise over 30 minutes with trifluoromethanesulfonic anhydride (18.4 g, 65.2 mmol), warmed to room temperature, stirred for 22 hours, and transferred to 10% NaHCO₃ (200 mL). The organic phase was separated, and the aqueous phase was extracted with dichloromethane (30 mL). The combined extracts were washed with brine (30 mL), dried (MgSO₄), filtered through silica gel with 1:1 hexane/dichloromethane rinses, and concentrated. The concentrate was purified by flash column chromatography eluting with 98:2 hexane/ethyl acetate to provide 9.56 g of the desired product.

MS (ESI(-)) m/z 284 (M-H)⁻;

¹H NMR (CDCl₃) δ 2.67 (s, 3H), 7.26-7.31 (m, 2H), 8.08-8.12 (m, 1H).

Example 72B7-methyl-5-indolyl trifluoromethanesulfonate

A solution of 3-methyl-4-nitrophenyl trifluoromethanesulfonate (8.96 g, 31.4 mmol) in THF (200 mL) at 0 °C was treated dropwise with 1M allylmagnesium bromide in THF (110 mL 110 mmol), stirred for 2 hours, transferred into saturated NH₄Cl (200 mL), and extracted with ethyl acetate (200 mL). The extract was dried (MgSO₄), filtered, and concentrated. The concentrate was purified by flash column chromatography with 9:1 hexanes/ ethyl acetate to provide 3.19 g of the desired product.

MS (ESI(-)) m/z 278 (M-H)⁻;

¹H NMR (CDCl₃) δ 2.51 (s, 3H), 6.60 (t, J=2.8 Hz, 1H), 6.91 (d, J=1.8 Hz, 1H), 7.30 (t, J=2.8 Hz, 1H), 7.39 (d, J=1.8 Hz, 1H), 8.28-8.14 (br, H).

Example 72C7-methyl-5-indolecarboxylic acid

A solution of 7-methyl-5-indolyl trifluoromethanesulfonate (3.19 g, 11.4 mmol), triethylamine, and 1,1'-bis(diphenylphosphino)ferrocene palladium (II) chloride (catalytic) in 9:1 THF/water was stirred under CO₂ (500 psi) until HPLC indicated complete conversion. The solution was treated with water (30 mL), adjusted to pH 4-5, and extracted sequentially with ethyl acetate (100 mL) and dichloromethane (3×40 mL). The combined extracts were dried (Na₂SO₄), filtered, and concentrated to provide the desired product which was used in the next step without further purification.

Example 72D2-(7-methyl-5-indolyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

Example 72C was processed as described in Example 63E to provide the desired product.

¹H NMR (DMSO-d₆) δ 2.44 (s, 3H), 3.59 (s, 3H), 3.68 (s, 6H), 3.78 (dd, J=7.8, 14.6 Hz, 1H), 4.29 (dd, J=10.0, 14.6 Hz, 1H), 5.58 (dd, J=7.8, 10.8 Hz, 1H), 6.47-6.49 (m, 1H), 6.61 (s, 2H), 7.34 (app t, J=2.8 Hz, 1H), 7.46 (s, 1H), 7.94 (s, 1H), 11.27 (s, 1H);
HRMS (FAB) Calc. (M+H)⁺ for C₂₁H₂₃N₂O₄:367.1658. Found. 367.1668.
Anal. calcd for C₂₁H₂₂N₂O₄ 0.45 H₂O: C, 67.35; H, 6.16; N, 7.48. Found: C, 67.29; H, 6.21; N, 7.45.

Example 73

2-(1,7-dimethyl-5-indolyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

Example 72 (141 mg, 0.385 mmol) was processed as described Example 64 to provide 113 mg of the desired product.

¹H NMR (DMSO-d₆) δ 2.76 (s, 3H), 3.64 (s, 3H), 3.74 (s, 6H), 3.85 (dd, J=7.8, 14.6 Hz, 1H), 4.07 (s, 3H), 4.36 (dd, J=9.8, 14.6 Hz, 1H), 5.64 (dd, J=7.8, 9.8 Hz, 1H), 6.48 (d, J=3.0 Hz, 1H), 6.67 (s, 2H), 7.30 (d, J=3.0 Hz, 1H), 7.46 (s, 1H), 7.95 (d, J=1.3 Hz, 1H);
5 HRMS (FAB) Calc. (M+H)⁺ for C₂₂H₂₅N₂O₄: 381.1814. Found: 381.1824.
Anal. calcd for C₂₂H₂₄N₂O₄: C, 69.46; H, 6.36; N, 7.36. Found: C, 69.20; H, 6.43; N, 7.12.

10

Example 74

2-(1,2,7-trimethylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

3-Methyl-4-aminobenzoate was processed as described in Examples 71A-D to provide the desired product.

¹H NMR (CDCl₃) δ 2.40 (s, 3H), 2.79 (s, 3H), 3.83 (s, 6H), 3.84 (s, 3H), 3.95 (s, 3H),
15 3.95-4.02 (m, 1H), 4.45 (dd, J=10.0, 14.6 Hz, 1H), 5.56 (dd, J=7.8, 10.0 Hz, 1H), 6.29 (d, J=1.0 Hz, 1H), 6.59 (s, 2H), 7.55-7.57 (m, 1H), 8.00-8.01 (m, 1H);
HRMS (FAB) Calc. (M+H)⁺ for C₂₃H₂₇N₂O₄: 395.1971. Found: 395.1962.
Anal. calcd for C₂₃H₂₆N₂O₄ 0.65 H₂O: C, 68.01; H, 6.77; N, 6.90. Found: C, 68.08; H, 6.40; N, 6.61.

20

Example 75

2-(1,2-dimethylbenzimidazol-5-yl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

Example 75A

25

methyl 3-amino-4-methylaminobenzoate

A solution of methyl 3,4-dinitrobenzoate (38.9 g, 172 mmol) in methanol (200 mL) at

0 °C was treated with 2M methylamine in methanol (350 mL 700 mmol) warmed to room temperature, stirred for 64 hours, and concentrated. The concentrate was slurried in
30 methanol (100 mL), treated with 10% Pd/C (10 g, 9.4 mmol), stirred under hydrogen (1 atm) for 22 hours, diluted with ethyl acetate (1 L), filtered through silica gel, and concentrated to provide 27.0 g of the desired product.

MS (DCI/NH₃) m/z 181 (M+H)⁺;

¹H NMR (DMSO-d₆) δ 2.77 (d, J=5.1 Hz, 3H), 3.72 (s, 3H), 4.67 (s, 2H), 5.39 (q, J=5.1
35 Hz, 1H), 6.39 (d, J=8.4 Hz, 1H), 7.18 (d, J=2.1 Hz, 1H), 7.25 (dd, J=2.1, 8.4 Hz, 1H).

Example 75Bmethyl 3-acetylamino-4-methylaminobenzoate

A solution of Example 75A (1.80 g, 10.0 mmol) in dichloromethane (100 mL) was
5 treated sequentially with acetic anhydride (3.06 g, 30.0 mmol) and 10% NaHCO₃ (100
mL) and stirred for 30 minutes. The organic layer was separated, washed with brine (30
mL), dried (MgSO₄), filtered, concentrated until solid precipitated, treated with diethyl
ether, and filtered to provide 1.66 g of desired product.

MS (ESI(+)) m/z 223 (M+H)⁺;

10 ¹H NMR (DMSO-d₆) δ 2.04 (s, 3H), 2.78 (d, J=5.4 Hz, 3H), 3.75 (s, 3H), 5.93 (q, J=5.4
Hz, 1H), 6.60 (d, J=8.5 Hz, 1H), 7.67 (dd, J=1.7, 8.5 Hz, 1H), 7.70 (d, J=1.7 Hz, 1H),
9.07 (s, 1H).

Example 75Cmethyl 1,2-dimethylbenzimidazole-5-carboxylate

A solution of Eaton's reagent (1:10 P₂O₅/methane sulfonic acid) (30 mL) was
treated portionwise with Example 75B (1.66 g, 7.47 mmol), heated to 110 °C for 1 hour,
transferred to 10% NaHCO₃ (300 mL), and extracted with ethyl acetate (300 mL then
2×100 mL). The combined extracts were washed with brine (100 mL), dried (MgSO₄),
20 filtered, and concentrated to provide 987 mg of the desired product as a solid.

MS (ESI(-)) m/z 383 (M-H)⁻;

¹H NMR (DMSO-d₆) δ 3.71 (s, 3H), 3.83-3.86 (m, 9H), 7.01 (s, 2H), 7.48-7.64 (m, 2H),
7.70 (dd, J=1.7, 8.5 Hz, 1H), 8.41 (s, 1H), 11.17 (s, 1H), 11.80 (s, 1H).

Example 75D2-(1,2-dimethylbenzimidazol-5-yl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

Example 75C was processed as described in Examples 63D and 63E to provide the
desired product.

¹H NMR (DMSO-d₆) δ 2.56 (s, 3H), 3.65 (s, 3H), 3.75 (s, 6H), 3.77 (s, 3H), 3.88 (dd,
30 J=8.1, 14.7 Hz, 1H), 4.39 (dd, J=10.0, 14.7 Hz, 1H), 5.69 (dd, J=8.1, 10.0 Hz, 1H), 6.70
(s, 2H), 7.58 (d, J=8.8 Hz, 1H), 7.83 (dd, J=1.5, 8.8 Hz, 1H), 9.05 (d, J=1.5 Hz, 1H).
HRMS (FAB) Calc. (M+H)⁺ for C₂₁H₂₄N₃O₄: 382.1767. Found: 382.1750.

Example 762-(3-trifluoroacetyl-5-indolyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

Example 76Amethyl 3-trifluoroacetyl-5-indolecarboxylate

A solution of trifluoroacetic anhydride (5.25 g, 25.0 mmol) in dichloroethane (50 mL) at 0 °C was treated with methyl 5-indolecarboxylate (0.876 g, 5.0 mmol), warmed gradually to room temperature, stirred for 24 hours, and treated with pentane to provide 1.06 g of the desired product.
MS (ESI(+)) m/z 272 (M+H)⁺.

Example 76B2-(3-trifluoroacetyl-5-indolyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

Example 76A was processed as described in Examples 63D and 63E to provide 279 mg of the desired product.

¹H NMR (CDCl₃) δ 3.86 (s, 6H), 3.87 (s, 3H), 4.03-4.05 (m, 1H), 4.53 (dd, J=10.0, 14.6 Hz, 1H), 5.70 (dd, J=8.2, 10.0 Hz, 1H), 6.62 (s, 2H), 7.44 (d, J=8.5 Hz, 1H), 8.00 (dd, J=1.3, 8.5 Hz, 1H), 9.08 (d, J=1.3 Hz, 1H), 9.00 (s, 1H), 10.60 (s, 1H).
HRMS (FAB) Calc. (M+H)⁺ for C₂₂H₂₀F₃N₂O₅: 449.1324. Found 449.1330.

Example 772-(1-methyl-3-trifluoroacetylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

Methyl 1-methyl-5-indolecarboxylate was processed as described in Example 76A to provide 325 mg of the desired product.

¹H NMR (DMSO-d₆) δ 3.66 (s, 3H), 3.76 (s, 6H), 3.94 (dd, J=7.9, 14.9 Hz, 1H), 4.00 (s, 3H), 4.42 (dd, J=9.9, 14.7 Hz, 1H), 5.70 (dd, J=7.9, 9.9 Hz, 1H), 6.71 (s, 2H), 7.80 (d, J=8.7, 1H), 8.02 (dd, J=1.6, 8.7 Hz, 1H), 8.69 (d, J=1.6 Hz, 1H), 8.77-8.78 (m, 1H);
HRMS (FAB) Calc. (M+H)⁺ for C₂₃H₂₂F₃N₂O₅: 463.1481. Found: 463.1470.
Anal. calcd for C₂₃H₂₁F₃N₂O₅: C, 59.74; H, 4.58; N, 6.06. Found: C, 59.50; H, 4.76; N, 6.00.

Example 782-(1-(2,2,2-trifluoroethyl)indol-5-yl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazolineExample 78A5-benzyloxy-1-trifluoroacetylindole

A solution of trifluoroacetic anhydride (12.7 g, 60.0 mmol) in dichloroethane (80 mL) at 0 °C was treated dropwise with a solution of 5-benzyloxyindole (3.34 g, 15.0 mmol) in dichloroethane (40 mL), stirred for 18 hours, diluted with ethyl acetate (200 mL), washed sequentially with 10% NaHCO₃ (300 mL), 2:1:1 water/10% NaHCO₃/brine (2×100 mL), and brine (50 mL), dried (MgSO₄), filtered, and concentrated to provide 2.33 g of the desired product.

MS (ESI(-)) m/z 318 (M-H)⁻;

¹H NMR (DMSO-d₆) δ 5.18 (s, 2H), 6.93 (d, J=4.1 Hz, 1H), 7.13 (dd, J=2.6, 8.8 Hz, 1H), 7.32-7.36 (m, 2H), 7.37-7.43 (m, 2H), 7.45-7.50 (m, 2H), 7.71-7.75 (m, 1H), 8.21 (d, J=8.8 Hz, 1H).

Example 78B

5-benzyloxy-1-(2,2,2-trifluoroethyl)indole

A solution of Example 78A (1.98 g, 6.20 mmol) in THF (20 mL) at 0 °C was treated dropwise with 1M BH₃·THF in THF (11.2 mL, 11.2 mmol), heated at reflux for 16 hours, cooled to 0 °C, treated 6M HCl (approximately 1 mL), diluted with ethyl acetate (60 mL), washed with 10% NaHCO₃ (30 mL) and brine (30 mL), dried (MgSO₄), filtered, and concentrated to provide 1.56 g of the desired compound.

MS (ESI(+)) m/z 306 (M+H)⁺;

¹H NMR (DMSO-d₆) δ 5.10 (s, 2H), 5.18 (q, J=9.4 Hz, 2H), 6.44 (d, J=3.3 Hz, 1H), 6.92 (dd, J=2.2, 9.0 Hz, 1H), 7.16 (d, J=2.2 Hz, 1H), 7.29-7.38 (m, 2H), 7.38-7.42 (m, 2H), 7.44-7.52 (m, 3H).

Example 78C

5-hydroxy-1-(2,2,2-trifluoroethyl)indole

A solution of 5-benzyloxy-1-(2,2,2-trifluoroethyl)indole (1.56 g, 4.09 mmol) in dichloromethane (10 mL) at 0 °C was treated dropwise with 1M BBr₃ in dichloromethane (5.73 mL, 5.73 mmol), stirred for 2 hours, transferred to 2:1:1 water/10% NaHCO₃/brine (100 mL), and extracted with ethyl acetate (100 mL). The extract was washed with brine (40 mL), dried (MgSO₄), filtered, and concentrated. The concentrate was purified by flash column chromatography with 9:1 hexane/ ethyl acetate to provide 118 mg of the desired product.

MS (ESI(+)) m/z 218 (M+H)⁺;

¹H NMR (CDCl₃) δ 4.59 (q, J=6.2 Hz, 2H), 6.47 (d, J=3.0 Hz, 1H), 6.84 (dd, J=2.4, 8.8 Hz, 1H), 7.04 (d, J=2.4 Hz, 1H), 7.07 (d, J=3.0 Hz, 1H), 7.21 (d, J=8.8 Hz, 1H).

Example 78D1-(2,2,2-trifluoroethyl)-5-indolyl trifluoromethanesulfonate

5-Hydroxy-1-(2,2,2-trifluoroethyl)indole (114 mg, 0.53 mmol) was processed as described in Example 76A to provide 84.3 mg of the desired product.

5 MS (ESI(+)) m/z 349 (M+H)⁺;

¹H NMR (CDCl₃) δ 4.66 (q, J=8.5 Hz, 2H), 6.66 (d, J=3.4 Hz, 1H), 7.17 (dd, J=2.4, 8.8 Hz, 1H), 7.22 (d, J=3.4 Hz, 1H), 7.37 (d, J=8.8 Hz, 1H), 7.55 (d, J=2.4 Hz, 1H).

Example 78E

10 1-(2,2,2-trifluoroethyl)-5-indolecarboxylic acid

A solution of 1-(2,2,2-trifluoroethyl)-5-indolyl trifluoromethanesulfonate (84.3 mg, 0.243 mmol) and 1,1'-bis(diphenylphosphino)ferrocene palladium (II) (catalytic) in methanol was stirred under carbon dioxide (500 psi), until HPLC indicated complete conversion, and concentrated. The concentrate was hydrolyzed as described previously to

15 provide 59.1 mg of the desired product.

¹H NMR (CDCl₃) δ 4.70 (q, J=8.5 Hz, 2H), 6.74 (d, J=3.3 Hz, 1H), 7.20 (d, J=3.3 Hz, 1H), 7.28 (d, J=8.5 Hz, 1H), 7.40 (d, J=8.5 Hz, 1H), 8.04 (dd, J=0.9, 8.5 Hz, 1H), 8.49 (s, 1H).

20

Example 78F2-(1-(2,2,2-trifluoroethyl)indol-5-yl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazoline

1-(2,2,2-Trifluoroethyl)-5-indolecarboxylic acid (71.5 mg, 0.294 mmol) was processed as described in Example 4 to provide 20.4 mg of the desired product.

25 ¹H NMR (DMSO-d₆) δ 3.65 (s, 3H), 3.75 (s, 6H), 3.87 (dd, J=7.6, 14.8 Hz, 1H), 4.39 (dd, J=10.0, 14.8 Hz, 1H), 5.25 (q, J=9.5 Hz, 2H), 5.66 (dd, J=7.6, 10.0 Hz, 1H), 6.67-6.70 (m, 3H), 7.49 (d, J=3.4 Hz, 1H), 7.70 (d, J=8.8 Hz, 1H), 7.82 (dd, J=1.4, 8.8 Hz, 1H), 8.19 (d, J=1.4 Hz, 1H).

HRMS (FAB) Calc. (M+H)⁺ for C₂₂H₂₂F₃N₂O₄: 435.1532. Found: 435.1537. H

30

Example 792-(1-cyclopropyl-5-indolyl)-5-(3,4,5-trimethoxyphenyl)-Δ2,3-oxazolineExample 79A3-bromo-4-cyclopropylaminobenzonitrile

35 A solution of 3-bromo-4-fluorobenzonitrile (9.33 mmol) and cyclopropylamine (7.90 g, 136 mmol) in methanol (60 mL) was heated to 60 °C for 20 hours and

concentrated. The concentrate was purified by flash column chromatography with 96:4 hexane/ethyl acetate to provide 2.63 g of the desired product.

MS (ESI(+)) m/z 239 ($M+H$)⁺;

¹H NMR (CDCl₃) δ 0.59-0.64 (m, 2H), 0.85-0.91 (m, 2H), 2.46-2.54 (m, 1H), 5.16-5.22 (br s, 1H), 7.03 (d, $J=8.6$ Hz, 1H), 7.47 (dd, $J=1.9, 8.6$ Hz, 1H), 7.66 (d, $J=1.9$ Hz, 1H).

Example 79B

1-cyclopropyl-5-cyanoindole

A solution of 40% by weight ethyl ethynyl ether (5.00 g, 28.5 mmol) in hexanes at 0 °C was treated dropwise with 1M catecholborane in THF (27.4 mL, 27.4 mmol), warmed to room temperature for 2 hours, heated at 70 °C for 2 hours, treated sequentially with a solution of 79A (1.35 g, 5.70 mmol) in THF (25 mL), 1,1'-bis(diphenylphosphino)ferrocene palladium (II) chloride (0.233 g, 0.285 mmol), and CsF (3.04 g, 20.0 mmol), stirred for 22 hours, treated with double the amount of catalyst and base, stirred for 20 hours, cooled to room temperature, treated with diethyl ether to double the reaction volume, filtered through silica gel, and concentrated. The concentrate was dissolved in THF (10 mL), treated with 2M HCl (10 mL), stirred for 2 days, transferred to 10% NaHCO₃ (100 mL), and extracted with ethyl acetate (100 mL then 3×30 mL). The combined extracts were washed with brine (50 mL), dried (MgSO₄), filtered through silica gel with ethyl acetate rinses, and concentrated. The concentrate was purified by radial chromatography with 9:1 hexane/ethyl acetate to provide 291 mg of the desired product.

MS (ESI(+)) m/z 183 ($M+H$)⁺;

¹H NMR (CDCl₃) δ 0.98-1.06 (m, 2H), 1.09-1.17 (m, 2H), 3.34-3.42 (m, 1H), 6.50 (d, $J=3.3$ Hz, 1H), 7.24 (d, $J=3.3$ Hz, 1H), 7.44 (dd, $J=0.9, 8.1$ Hz, 1H), 7.61 (dd, $J=0.9, 8.1$ Hz, 1H), 7.94 (app t, $J=0.9$ Hz, 1H).

Example 79C

2-(1-cyclopropyl-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline


Example 79B (291 mg, 1.60 mmol) was processed as described in Example 23F to provide 23 mg of the desired product.

¹H NMR (CDCl₃) δ 1.00-1.06 (m, 2H), 1.07-1.14 (m, 2H), 3.34-3.41 (m, 1H), 3.84 (s, 6H), 3.85 (s, 3H), 4.00 (dd, $J=7.6, 14.6$ Hz, 1H), 4.48 (dd, $J=10.2, 14.6$ Hz, 1H), 5.59 (dd, $J=7.6, 10.2$ Hz, 1H), 6.49 (dd, $J=0.7, 3.4$ Hz, 1H), 6.59 (s, 2H), 7.17 (d, $J=3.4$ Hz, 1H), 7.59 (d, $J=8.8$ Hz, 1H), 7.93 (dd, $J=1.4, 8.8$ Hz, 1H), 8.29 (d, $J=1.4$ Hz, 1H);
HRMS (FAB) Calc. ($M+H$)⁺ for C₂₃H₂₅N₂O₄: 393.1814. Found: 393.1820.

Anal. calcd for $C_{23}H_{24}N_2O_4 \cdot 0.30H_2O$: C, 65.04; H, 5.87; N, 7.22. Found: C, 65.06; H, 5.88; N, 7.20.

WHAT IS CLAIMED IS:

1. A compound having Formula I



or a pharmaceutically acceptable salt or prodrug thereof, wherein R^A , R^B , and R^C are independently selected from the group consisting of

- (1) alkyl,
 (2) alkoxy,
 and
 (3) thioalkoxy;

R^D and R^E are independently selected from the group consisting of

- (1) hydrogen
 and
 (2) alkyl;

R^2 is selected from the group consisting of

- (1) aryl,
 (2) heterocycle,

wherein (1) and (2) can be optionally substituted with one, two, three, four, or five substituents independently selected from $-L^1R^6$ wherein L^1 is selected from the group consisting of

- (a) a covalent bond,
 (b) $-C(X)-$, wherein X is O or S,
 (c) $-S(O)_t-$, wherein t is 0, 1, or 2,
 (d) $-NR^3-$, wherein R^3 is selected from the group consisting of

- (i) hydrogen,
 (ii) carboxaldehyde,
 (iii) alkanoyl,
 (iv) alkoxycarbonyl,

- (v) $-C(O)OR^{11}$, wherein R^{11} is alkyl which can be optionally substituted with one or two aryl substituents,
- (vi) cycloalkyl,
- 35 (vii) alkyl, wherein the alkyl can be optionally substituted with one or two substituents independently selected from the group consisting of
- (1') alkoxy,
- (2') cycloalkyl,
- and
- 40 (3') aryl, wherein the aryl can be optionally substituted with one or two substituents independently selected from the group consisting of
- (a') alkanoyloxy,
- (b') hydroxy,
- 45 and
- (c') alkoxy,
- (viii) alkenyl,
- (ix) alkynyl,
- (x) $-OR^5$ wherein R^5 is selected from the group consisting of
- 50 (1') hydrogen,
- and
- (2') alkyl, wherein the alkyl can be optionally substituted with one or two substituents independently selected from the group consisting of
- 55 (a') aryl,
- (b') cycloalkyl,
- and
- (c') hydroxyl,
- (xi) a nitrogen protecting group,
- 60 (xii) aryl,
- and
- (xiii) $-C(O)R^{13}$, wherein R^{13} is perfluoroalkyl,
- (e) $-O-$,
- (f) $-X'C(X)-$, wherein X is defined previously and X' is O or S,
- 65 (g) $-C(X)X-$,
- (h) $-N(R^{3'})C(O)N(R^{4'})-$ wherein $R^{3'}$ and $R^{4'}$ are independently selected from the group consisting of

- (i) hydrogen
and
70 (ii) alkyl,
(i) $-N(R^{3'})C(X)-$, wherein $R^{3'}$ is defined above,
(j) $-C(X)N(R^{3'})-$, wherein $R^{3'}$ is defined above,
(k) $-NR^{3'}S(O)_t-$, wherein $R^{3'}$ is defined above,
and
75 (l) $-S(O)_tNR^{3'}$ - wherein t and $R^{3'}$ are defined above,
wherein (a)-(l) are drawn with their left ends attached to $-L^1-$ and their right ends
attached to R^6 , and R^6 is selected from the group consisting of
(a) $-CO_2R^5$, wherein R^5 is defined above,
(b) $-C(O)R^5$, wherein R^5 is defined above,
80 (c) $-OC(O)R^{10}$, wherein R^{10} is alkyl which can be optionally substituted with
one or two substituents selected from the group consisting of
(i) alkoxy
and
(ii) hydroxy,
85 (d) cyano,
(e) nitro,
(f) $-XH$,
(g) halo,
(h) $-S(O)_tNR^3R^4$, wherein R^3 is defined above, t' is one or two, and R^4 is selected
90 from the group consisting of
(i) hydrogen,
(ii) carboxaldehyde,
(iii) alkanoyl,
(iv) $-C(O)OR^{10}$, wherein R^{10} is defined above,
95 (v) $-C(O)OR^{11}$, wherein R^{11} is defined above,
(vi) cycloalkyl,
(vii) alkyl, wherein the alkyl can be optionally substituted with one or two
substituents independently selected from the group consisting of
(1') $-OR^{10}$, wherein R^{10} is defined above,
100 (2') cycloalkyl,
and
(3') aryl, wherein the aryl can be optionally substituted with one or
two substituents independently selected from the group

- consisting of
- 105 (a') $-\text{OC}(\text{O})\text{R}^{10}$, wherein R^{10} is defined above,
- (b') hydroxyl,
- and
- (c') $-\text{OR}^{10}$, wherein R^{10} is defined above,
- (viii) alkenyl,
- 110 (ix) alkynyl,
- and
- (x) $-\text{OR}^5$, wherein R^5 is defined above,
- (i) $-\text{NR}^3\text{R}^4$, wherein R^3 and R^4 are defined above,
- (j) perfluoroalkyl,
- 115 (k) alkenyl,
- (l) alkynyl,
- (m) aryl,
- (n) heterocycle,
- (o) alkyl,
- 120 (p) cycloalkyl,
- and
- (q) $=\text{X}$, wherein X is defined above,
- wherein (k)-(o) can be optionally substituted with one, two, three, four, or five
- substituents independently selected from the group consisting of
- 125 (i) hydroxyl,
- (ii) halo,
- (iii) $-\text{OR}^{10}$, wherein R^{10} is defined above,
- (iv) $-\text{SR}^{10}$, wherein R^{10} is defined above,
- (v) $-\text{CO}_2\text{R}^5$, wherein R^5 is defined above,
- 130 (vi) $-\text{CHO}$,
- (vii) $=\text{X}$, wherein X is defined above,
- (viii) $-\text{N}_3$,
- (ix) $=\text{C}(\text{H})\text{NR}^3\text{R}^4$, wherein R^3 and R^4 are defined above,
- (x) cyano,
- 135 (xi) $=\text{NOR}^3$, wherein R^3 is defined above,
- (xii) $-\text{NR}^3\text{R}^4$, wherein R^3 and R^4 are defined above,
- (xiii) $-\text{S}(\text{O})_t\text{NR}^3\text{R}^4$, wherein R^3 and R^4 are defined above,
- (xiv) nitro,
- (xv) aryl,

- 140 and
 (xvi) heterocycle,
 (4) cycloalkyl,
 and
 (5) cycloalkenyl,
 145 wherein (4) and (5) can be optionally substituted with one, two, three, or four
 substituents independently selected from the group consisting of
 (a) alkyl,
 (b) hydroxyl,
 and
 150 (c) aryl.

2. A compound according to Claim 1 wherein R² is aryl and the aryl can be
 optionally substituted.
3. A compound according to Claim 2 selected from the group consisting of
 2-(4-dimethylaminophenyl)-5-(3,4,5-trimethoxyphenyl)-Δ²,3-oxazoline,
 2-(3-hydroxy-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ²,3-oxazoline,
 2-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ²,3-oxazoline,
 5 2-(3,5-dimethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ²,3-oxazoline,
 2-(4-amino-3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ²,3-oxazoline,
 2-(4-amino-3-methylphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ²,3-oxazoline,
 2-(3-hydroxy-4-methoxyphenyl)-4-dimethyl-5-(3,4,5-trimethoxyphenyl)-Δ²,3-
 oxazoline,
 10 2-(4-ethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ²,3-oxazoline,
 2-(3,4-dimethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ²,3-oxazoline,
 2-(4-benzyloxy-3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ²,3-oxazoline,
 2-(3-acetoxy-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ²,3-oxazoline,
 2-(3-amino-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ²,3-oxazoline,
 15 2-(3-amino-4-methylphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ²,3-oxazoline,
 2-(3-(Ala-Ala-amino-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ²,3-
 oxazoline,
 2-(3-(Ala-amino-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ²,3-oxazoline,
 2-(3-((3-aminopropionoyl)amino-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-
 20 Δ²,3-oxazoline,
 2-(3-(Ser-amino-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ²,3-oxazoline,
 2-(3-(Gly-amino-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-Δ²,3-oxazoline,

- 25 and
- 2-(3-fluoro-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(2-chloro-4-nitrophenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(2-fluoro-4-nitrophenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline.
4. A compound according to Claim 1 wherein R² is heterocycle and the heterocycle can be optionally substituted.
5. A compound according to Claim 4 selected from the group consisting of
2-(3-acetylmethylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(1-methylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(indol-3-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
5 2-(indol-2-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(1-methoxymethylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(indol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(N-methyl-tetrahydroquinol-6-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(2,3-dihydro-5-bromo-7-benzofuranyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-
10 oxazoline,
2-(1-methyl-2,3-dihydro-indol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(1-methylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline, hydrochloride,
(5S)-2-(1-methylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
(5R)-2-(1-methylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
15 2-(1-ethylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(6-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(1-methylindol-6-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(4-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(1-methylindol-4-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
20 2-(7-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(1-methylindol-7-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(1-methylindol-3-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(1-methyl-indol-2-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(6-quinoliny)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
25 2-(3-quinoliny)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(4-quinoliny)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(1-isoquinoliny)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(1-methyl-1*H*-pyridin-2-on-4-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,

2-(2-(2-hydroxyethyloxy)-4-pyridinyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-
 30 oxazoline,
 2-(imidazo[1,2-a]pyridin-6-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(imidazo[1,5-a]pyridin-6-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(2-methyl-6-indoliziny)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-((2S)-indolin-2-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 35 2-(1,4-dimethylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 (2-(1-methylthiothiocarbonylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-
 oxazoline,
 2-(1,3-dimethylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(6-chloroindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 40 2-(1-methyloxindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(1-methyl-6-chloroindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(1-difluoromethylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(3-chloro-1-methylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(7-fluoro-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 45 2-(1-methyl-7-fluoro-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(7-chloro-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(1-methyl-7-chloro-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(3-fluoro-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 (2-(1-methyl-3-fluoro-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 50 2-(1-hydroxymethylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(1-methoxymethyl-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(1,2-dimethyl-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(7-methyl-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(1,7-dimethyl-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 55 2-(1,2,7-trimethylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(1,2-dimethylbenzimidazol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(3-trifluoroacetyl-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 (2-(1-methyl-3-trifluoroacetylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-
 oxazoline,
 60 2-(1-(2,2,2-trifluoroethyl)indol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 and
 2-(1-cyclopropyl-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline.

6. A compound according to Claim 1 wherein R² is cycloalkyl of three to eight carbons and the cycloalkyl can be optionally substituted.

7. A compound according to Claim 6 which is
2-(2-methyl-cyclopropyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline.
8. A method for treating cancer comprising administering an effective amount
of a compound of Claim 1.
9. A compound selected from the group consisting of
2-(4-dimethylaminophenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(3-hydroxy-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
5 2-(3,5-dimethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(3-acetylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(1-methylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(indol-3-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(indol-2-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
10 2-(1-methoxymethylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(4-amino-3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(indol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(4-amino-3-methylphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(3-hydroxy-4-methoxyphenyl)-4-dimethyl-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-
15 oxazoline,
2-(N-methyl-tetrahydroquinol-6-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(2-methyl-cyclopropyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(4-ethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(3,4-dimethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
20 2-(4-benzyloxy-3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(2,3-dihydro-5-bromo-7-benzofuranyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-
oxazoline,
2-(3-acetoxy-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(1-methyl-2,3-dihydro-indol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
25 2-(1-methylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline, hydrochloride,
(5S)-2-(1-methylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
(5R)-2-(1-methylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(1-ethylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(6-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
30 2-(1-methylindol-6-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,

- 2-(4-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(1-methylindol-4-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(7-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(1-methylindol-7-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 35 2-(1-methylindol-3-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(1-methyl-indol-2-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(6-quinoliny)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(3-quinoliny)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(4-quinoliny)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 40 2-(1-isoquinoliny)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(3-amino-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(3-amino-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(3-(Ala-Ala-amino-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-
 oxazoline,
 45 2-(3-(Ala-amino-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(3-((3-aminopropionoyl)amino-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-
 Δ 2,3-oxazoline,
 2-(3-(Ser-amino-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(3-(Gly-amino-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 50 2-(1-methyl-1*H*-pyridin-2-on-4-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(2-(2-hydroxyethyloxy)-4-pyridiny)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-
 oxazoline,
 2-(imidazo[1,2-*a*]pyridin-6-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(imidazo[1,5-*a*]pyridin-6-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 55 2-(2-methyl-6-indoliziny)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(3-fluoro-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-((2*S*)-indolin-2-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(2-chloro-4-nitrophenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(2-fluoro-4-nitrophenyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline.
 60 2-(1,4-dimethylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 (2-(1-methylthiothiocarbonylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-
 oxazoline,
 2-(1,3-dimethylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(6-chloroindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 65 2-(1-methyloxindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(1-methyl-6-chloroindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
 2-(1-difluoromethylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,

- 2-(3-chloro-1-methylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(7-fluoro-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
70 2-(1-methyl-7-fluoro-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(7-chloro-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(1-methyl-7-chloro-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(3-fluoro-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
(2-(1-methyl-3-fluoro-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
75 2-(1-hydroxymethylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(1-methoxymethyl-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(1,2-dimethyl-5-indolyl)-4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(7-methyl-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(1,7-dimethyl-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
80 2-(1,2,7-trimethylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(1,2-dimethylbenzimidazol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
2-(3-trifluoroacetyl-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
(2-(1-methyl-3-trifluoroacetylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-
oxazoline,
85 2-(1-(2,2,2-trifluoroethyl)indol-5-yl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline,
and
2-(1-cyclopropyl-5-indolyl)-5-(3,4,5-trimethoxyphenyl)- Δ 2,3-oxazoline.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/16782

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D263/14 C07D413/04 A61K31/421 A61K31/422 C07D471/04
 C07D263/10 //(C07D471/04,235:00,221:00),(C07D471/04,221:00,
 209:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 596 326 A (DR KARLTHOMAE GMBH) 11 May 1994 (1994-05-11) claims 1-4,7,8 ---	1,8
A	EP 0 552 880 A (NORSK HYDRO AS) 28 July 1993 (1993-07-28) claims ---	1,8
A	NORTON P. PEET ET AL: "Synthesis of a 2,5-diaryloxazoline as a potential platelet-activating factor antagonist" JOURNAL OF HETEROCYCLIC CHEMISTRY., vol. 31, 1994, pages 419-423, XP002121432 HETEROCORPORATION. PROVO., US ISSN: 0022-152X the whole document -----	1,8

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

° Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"S" document member of the same patent family

Date of the actual completion of the international search

3 November 1999

Date of mailing of the international search report

18/11/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Henry, J

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 16782

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 8
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 8
is directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PL/US 99/16782

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0596326 A	11-05-1994	DE 4235590 A	28-04-1994
		DE 4303840 A	11-08-1994
		AT 126797 T	15-09-1995
		AU 665648 B	11-01-1996
		AU 4913593 A	05-05-1994
		CA 2108817 A	23-04-1994
		CN 1090849 A,B	17-08-1994
		CZ 9302236 A	18-05-1994
		DE 59300507 D	28-09-1995
		DK 596326 T	15-01-1996
		ES 2078787 T	16-12-1995
		FI 934665 A	23-04-1994
		GR 3017692 T	31-01-1996
		HK 1000285 A	20-02-1998
		HU 68958 A	28-08-1995
		IL 107342 A	13-07-1997
		JP 6192256 A	12-07-1994
		NO 933790 A	25-04-1994
		NZ 250018 A	26-07-1995
		PL 300834 A	16-05-1994
		SK 107393 A	07-09-1994
		US 5466687 A	14-11-1995
		ZA 9307806 A	21-04-1995
EP 0552880 A	28-07-1993	AT 165358 T	15-05-1998
		AU 657825 B	23-03-1995
		AU 3048592 A	22-07-1993
		CA 2087656 A	22-07-1993
		DE 69318046 D	28-05-1998
		DE 69318046 T	03-09-1998
		ES 2115722 T	01-07-1998
		JP 6040989 A	15-02-1994
		NO 302820 B	27-04-1998
		US 5534531 A	09-07-1996